WO2015066512A1 - Methods of treating hypertriglyceridemia - Google Patents

Methods of treating hypertriglyceridemia

Info

Publication number
WO2015066512A1
WO2015066512A1 PCT/US2014/063494 US2014063494W WO2015066512A1 WO 2015066512 A1 WO2015066512 A1 WO 2015066512A1 US 2014063494 W US2014063494 W US 2014063494W WO 2015066512 A1 WO2015066512 A1 WO 2015066512A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
mg
subject
baseline
dl
treatment
Prior art date
Application number
PCT/US2014/063494
Other languages
French (fr)
Inventor
Rene Braeckman
William STIRTAN
Paresh Soni
Original Assignee
Amarin Pharmaceuticals Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Abstract

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Description

TITLE

Methods of Treating Hypertriglyceridemia

PRIORITY CLAIM

[0001] This application claims priority to U.S. Provisional patent application serial no. 61/898, 133, filed on October 31, 2013, and U.S. Provisional patent application serial no. 61/900,078, filed on November 5, 2013, the entire contents of each of which are incorporated herein by reference and relied upon.

BACKGROUND

[0002] Cardiovascular disease is one of the leading causes of death in the United States and most European countries. It is estimated that over 70 million people in the United States alone suffer from a cardiovascular disease or disorder including but not limited to high blood pressure, coronary heart disease, dyslipidemia, congestive heart failure and stroke. A need exists for improved treatments for cardiovascular diseases and disorders.

SUMMARY

[0003] In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related diseases and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. In one embodiment, the composition contains not more than 10%, by weight,

docosahexaenoic acid or derivative thereof, substantially no docosahexaenoic acid or derivative thereof, or no docosahexaenoic acid or derivative thereof. In another embodiment, eicosapentaenoic acid ethyl ester comprises at least 96%, by weight, of all fatty acids present in the composition; the composition contains not more than 4%, by weight, of total fatty acids other than eicosapentaenoic acid ethyl ester; and/or the composition contains about 0.1% to about 0.6% of at least one fatty acid other than eicosapentaenoic acid ethyl ester and docosahexaenoic acid (or derivative thereof). [0004] In one embodiment, a pharmaceutical composition useful in accordance with the invention comprises, consists of or consists essentially of at least 95% by weight ethyl eicosapentaenoate (EPA-E), about 0.2% to about 0.5% by weight ethyl octadecatetraenoate (ODTA-E), about 0.05% to about 0.25% by weight ethyl nondecapentaenoate ( DPA-E), about 0.2% to about 0.45% by weight ethyl arachidonate (AA-E), about 0.3% to about 0.5% by weight ethyl eicosatetraenoate (ETA-E), and about 0.05% to about 0.32% ethyl heneicosapentaenoate (HPA-E). In another embodiment, the composition is present in a capsule shell. In another embodiment, the composition contains substantially no or no amount of

docosahexaenoic acid (DHA) or derivative thereof such as ethyl-DHA (DHA-E).

[0005] In another embodiment, the invention provides a method of treating moderate to severe hypertriglyceridemia comprising administering a composition as described herein to a subject in need thereof one to about four times per day.

[0006] In various embodiments, the present disclosure provides pharmaceutical compositions and methods of using such compositions to treat and/or prevent cardiovascular-related diseases. In one embodiment, the subject has a baseline fasting serum triglyceride level of at least about 500 mg/dL.

[0007] In some embodiments, the present disclosure provides a method of reducing a C-reactive protein level in a subject having metabolic syndrome and fasting triglycerides of at least 500 mg/dL, the method comprising identifying the subject as having metabolic syndrome, identifying the subject as having fasting triglycerides of at least 500 mg/dL, and orally administering to the subject about 4 g per day of ethyl eicosapentaenoate for a period of time effective to reduce a C-reactive protein ("CRP") level in the subject.

[0008] In various embodiments, the present disclosure provides pharmaceutical compositions and methods of using such compositions to treat and/or prevent cardiovascular-related diseases. In one embodiment, the subject is on concomitant statin therapy. In another embodiment, the subject on statin therapy has a baseline fasting serum triglyceride level of about 200 mg/dL to 499 mg/dL. [0009] In various embodiments, the present disclosure provides pharmaceutical compositions and methods of using such compositions to reduce a C-reactive protein level in a subject on statin therapy who has metabolic syndrome and fasting triglycerides of about 150 mg/dL to 499 mg/dL, the method comprising identifying the subject as having metabolic syndrome and as having fasting triglycerides of about 150 mg/dL to 499 mg/dL and thereafter orally administering to the subject about 4 g per day of ethyl eicosapentaenoate for a period of time effective to reduce a C-reactive protein level in the subject.

[0010] In various embodiments, the present disclosure provides pharmaceutical compositions and methods of using such compositions to treat a subject with mixed dyslipidemia and metabolic syndrome on statin therapy. In some embodiments, the method comprises identifying the subject as having mixed dyslipidemia and metabolic syndrome and thereafter administering to the subject about 4 dosage units per day, each dosage unit comprising about 900 mg to about 1.1 g of ethyl eicosapentaenoate for a period of at least about 12 weeks to effect a reduction in triglycerides.

[0011] In various embodiments, the present disclosure provides pharmaceutical compositions and methods of using such compositions to treat a subject with mixed dyslipidemia and metabolic syndrome on statin therapy. In some embodiments, the method comprises identifying the subject as having mixed dyslipidemia and metabolic syndrome and thereafter administering to the subject about 4 dosage units per day, each dosage unit comprising about 900 mg to about l. lg of ethyl eicosapentaenoate for a period of at least about 12 weeks as an adjunct to diet thereby to reduce one or more of CRP, triglycerides, non-HDL-C, Apo B, LDL-C, total cholesterol, and VLDL- C.

[0012] In various embodiments, the present disclosure provides pharmaceutical compositions and methods of using such compositions to lower triglycerides in a subject with mixed dyslipidemia and metabolic syndrome on statin therapy. In some embodiments, the method comprises identifying the subject as having mixed dyslipidemia and metabolic syndrome and thereafter administering to the subject about 4 dosage units per day, each dosage unit comprising about 900 mg to about 1.1 g of ethyl eicosapentaenoate wherein, in a clinical trial patient population that has mixed dyslipidemia and a fasting baseline triglyceride level of 200 mg/dl to about 500 mg/dl, administration of 4 g per day of the composition for 12 weeks is effective to reduce triglycerides compared to control.

[0013] In various embodiments, the present disclosure provides pharmaceutical compositions and methods of using such compositions to lower triglycerides and CRP in a subject having metabolic syndrome. In some embodiments, the method comprises identifying the subject as being on stable statin therapy and as having metabolic syndrome and fasting triglycerides of about 200 mg/dl to less than 500 mg/dl and thereafter administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 90%, by weight of all fatty acids present, ethyl eicosapentaenoate for a period of at least about 12 weeks to effect a reduction in fasting triglycerides and fasting CRP in the subject compared to fasting triglycerides and CRP in a second subject on stable statin therapy who has metabolic syndrome but has not received the pharmaceutical composition.

[0014] In various embodiments, the present disclosure provides pharmaceutical compositions and methods of using such compositions to lower triglycerides and CRP in a subject having metabolic syndrome. In some embodiments, the method comprises identifying the subject as being on stable statin therapy and as having metabolic syndrome and fasting triglycerides from about 200 mg/dl to less than 500 mg/dl and thereafter administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 90%, by weight of all fatty acids present, ethyl eicosapentaenoate for a period of at least about 12 weeks to effect a reduction in fasting triglycerides in the subject by least 5% and to effect a reduction in CRP in the subject by at least about 5% compared to fasting triglycerides and CRP, respectively, in a second subject on stable statin therapy who has metabolic syndrome but has not received the pharmaceutical composition.

[0015] In various embodiments, the present disclosure provides pharmaceutical compositions and methods of using such compositions to lower triglycerides in a subject on stable statin therapy and having metabolic syndrome and a fasting baseline triglyceride level from about 200 mg/dl to less than 500 mg/dl. In some embodiments, the method comprises identifying the subject as having metabolic syndrome and thereafter administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 90%, by weight of all fatty acids present, ethyl eicosapentaenoate for a period of 12 weeks, which when administered to a first patient population on stable statin therapy and having said baseline triglyceride level at 4 g per day for twelve weeks is effective to reduce fasting triglycerides and CRP, compared to fasting triglycerides and CRP observed in a second patient population on stable statin therapy and having metabolic syndrome and said fasting baseline triglyceride level who has not received the pharmaceutical composition.

[0016] In one embodiment, the disclosure provides a method of lowering triglycerides in a subject on stable statin therapy having baseline fasting triglycerides of about 200 mg/dl to less than 500 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising polyunsaturated fatty acids, for example about 1 g to about 4 g of EPA per day, wherein upon administering the composition to the subject daily for a period of 12 weeks the subject exhibits at least 5% lower fasting triglycerides than a control subject maintained on stable statin therapy (optionally with placebo matching the EPA) without concomitant EPA for a period of 12 weeks wherein the control subject also has baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl. In another embodiment, upon administering the composition to the subject daily for a period of 12 weeks the subject exhibits no serum LDL-C increase, no statistically significant serum LDL-C increase, a serum LDL-C decrease, or the subject is statistically non-inferior to the control subjects (statin plus optional placebo) in regard to serum LDL-C elevation).

[0017] These and other embodiments of the present invention will be disclosed in further detail herein below.

BRIEF DESCRIPTION OF THE DRAWING

[0018] FIG. 1A shows median percent change compared to baseline from baseline to week 12 for subjects having metabolic syndrome and baseline triglycerides of at least 500 mg/dl and no more than about 2000 mg/dl who receive 4 g per day of a composition according to the present disclosure. [0019] FIG. IB shows median percent change compared to baseline from baseline to week 12 for subjects having metabolic syndrome and baseline triglycerides of at least 500 mg/dl and no more than about 2000 mg/dl who receive 2 g per day of a composition according to the present disclosure.

[0020] FIG. 2 depicts median changes from baseline in hsCRP and other end points compared to placebo for subjects having metabolic syndrome and baseline

triglycerides of at least about 200 mg/dL and less than 500 mg/dL when administered 2 g/day or 4 g/day of a composition according to the present disclosure.

DETAILED DESCRIPTION

[0021] While the present invention is capable of being embodied in various forms, the description below of several embodiments is made with the understanding that the present disclosure is to be considered as an exemplification of the invention, and is not intended to limit the invention to the specific embodiments illustrated. Headings are provided for convenience only and are not to be construed to limit the invention in any manner. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.

[0022] The use of numerical values in the various quantitative values specified in this application, unless expressly indicated otherwise, are stated as approximations as though the minimum and maximum values within the stated ranges were both preceded by the word "about." Also, the disclosure of ranges is intended as a continuous range including every value between the minimum and maximum values recited as well as any ranges that can be formed by such values. Also disclosed herein are any and all ratios (and ranges of any such ratios) that can be formed by dividing a disclosed numeric value into any other disclosed numeric value. Accordingly, the skilled person will appreciate that many such ratios, ranges, and ranges of ratios can be unambiguously derived from the numerical values presented herein and in all instances such ratios, ranges, and ranges of ratios represent various embodiments of the present invention. [0023] In one embodiment, the invention provides a method for treatment and/or prevention of a cardiovascular-related disease. The term "cardiovascular-related disease" herein refers to any disease or disorder of the heart or blood vessels (i.e. arteries and veins) or any symptom thereof. Non-limiting examples of cardiovascular- related disease and disorders include hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease, vascular disease, stroke, atherosclerosis, arrhythmia, hypertension, myocardial infarction, and other cardiovascular events.

[0024] The term "treatment" in relation a given disease or disorder, includes, but is not limited to, inhibiting the disease or disorder, for example, arresting the development of the disease or disorder; relieving the disease or disorder, for example, causing regression of the disease or disorder; or relieving a condition caused by or resulting from the disease or disorder, for example, relieving, preventing or treating symptoms of the disease or disorder. The term "prevention" in relation to a given disease or disorder means: preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.

[0025] In one embodiment, the present invention provides a method of blood lipid therapy comprising administering to a subject or subject group in need thereof a pharmaceutical composition as described herein. In another embodiment, the subject or subject group has hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia and/or very high triglycerides.

In another embodiment, the subject or subject group being treated has a baseline triglyceride level (or median baseline triglyceride level in the case of a subject group), fed or fasting, of at least about 300 mg/dL, at least about 400 mg/dL, at least about 500 mg/dL, at least about 600 mg/dL, at least about 700 mg/dL, at least about 800 mg/dL, at least about 900 mg/dL, at least about 1000 mg/dL, at least about 1 100 mg/dL, at least about 1200 mg/dL, at least about 1300 mg/dL, at least about 1400 mg/dL, or at least about 1500 mg/dL, for example about 400 mg/dL to about 2500 mg/dL, about 450 mg/dL to about 2000 mg/dL or 500 mg/dL to about 1500 mg/dL. [0026] In another embodiment, the subject or subject group being treated has a baseline triglyceride level (or mean or median baseline triglyceride level in the case of a subject group), fed or fasting, of about 200 mg/dl to less than 500 mg/dl. In another embodiment, the subject or subject group has a baseline LDL-C level (or mean or median baseline LDL-C level), despite stable statin therapy, of about 40 mg/dl to about 115 or about 40 to about 100 mg/dl.

[0027] In one embodiment, the subject or subject group being treated in accordance with methods of the disclosure is on concomitant statin therapy, for example atorvastatin, rosuvastatin or simvastatin therapy (with or without ezetimibe). In another embodiment, the subject is on concomitant stable statin therapy at time of initiation of ultra-pure EPA therapy.

[0028] In another embodiment, the subject or subject group being treated in accordance with methods of the disclosure has a body mass index (BMI or mean BMI) of not more than about 45 kg/m2.

[0029] In one embodiment, the disclosure provides a method of lowering triglycerides in a subject on stable statin therapy having baseline fasting triglycerides of about 200 mg/dl to less than 500 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of EPA (e.g. ultra-pure EPA), wherein upon administering the composition to the subject daily for a period of about 12 weeks the subject exhibits at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75% lower fasting triglycerides than a control subject maintained on stable statin therapy (and optionally placebo matching the ultra-pure EPA) without concomitant ultra-pure EPA for a period of about 12 weeks, wherein the control subject also has baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl. The term "stable statin therapy" herein means that the subject, subject group, control subject or control subject group in question has been taking a stable daily dose of a statin (e.g. atorvastatin, rosuvastatin or simvastatin) for at least 4 weeks prior to the baseline fasting triglyceride measurement (the "qualifying period"). For example, a subject or control subject on stable statin therapy would receive a constant daily (i.e. the same dose each day) statin dose for at least 4 weeks immediately prior to baseline fasting triglyceride measurement. In one embodiment, the subject's and control subject's LDL-C is maintained between about 40 mg/dl and about 1 15 mg/dl or about 40 mg/dl to about 100 mg/dl during the qualifying period. The subject and control subject are then continued on their stable statin dose for the 12 week period post baseline.

[0030] In one embodiment, the statin is administered to the subject and the control subject in an amount of about 1 mg to about 500 mg, about 5 mg to about 200 mg, or about 10 mg to about 100 mg, for example about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, or about 10 mg; about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg. In another embodiment, the subject (and optionally the control subject) has a baseline LDL-C level, despite stable statin therapy, of about 40 mg/dl to about 1 15 mg/dl or about 40 mg/dl to about 100 mg/dl. In another embodiment, the subject and/or control subject has a body mass index (BMI; or mean BMI) of not more than about 45 kg/m2.

[0031] In another embodiment, the disclosure provides a method of lowering triglycerides in a subject group on stable statin therapy having mean baseline fasting triglycerides of about 200 mg/dl to less than 500 mg/dl, the method comprising administering to members of the subject group a pharmaceutical composition comprising about 1 g to about 4 g of ultra-pure EPA per day, wherein upon administering the composition to the members of the subject group daily for a period of about 12 weeks the subject group exhibits at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% lower mean fasting triglycerides than a control subject group maintained on stable statin therapy without concomitant ultra-pure EPA (optionally with matching placebo) for a period of about 12 weeks, wherein the control subject group also has mean baseline fasting triglycerides of about 200 mg/dl to less than 500 mg/dl. In a related embodiment, the stable statin therapy will be sufficient such that the subject group has a mean LDL-C level about at least about 40 mg/dl and not more than about 100 mg/dl or about 40 mg/dl to about 100 mg/dl for the 4 weeks immediately prior to the baseline fasting triglyceride measurement.

[0032] In another embodiment, the disclosure provides a method of lowering triglycerides in subject group on stable statin therapy and having a mean baseline fasting triglyceride level of about 200 mg/dl to less than 500 mg/dl, the method comprising administering to members of the subject group a pharmaceutical composition comprising about 1 g to about 4 g of ultra-pure EPA, wherein upon administering the composition to members of the subject group daily for a period of about 12 weeks the subject group exhibits: (a) at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% lower mean fasting triglycerides by comparison with a control subject group maintained on stable statin therapy without concomitant ultra-pure EPA (optionally with matching placebo) for a period of about 12 weeks, and (b) no serum LDL-C increase, no statistically significant serum LDL-C increase, a serum LDL-C decrease, or the subject is statistically non- inferior to the control subjects (statin plus optional placebo) in regard to serum LDL-C elevation) no increase in mean serum LDL-C levels compared to baseline, wherein the control subject also has mean baseline fasting triglycerides of about 200 mg/dl to less than 500 mg/dl.

[0033] In another embodiment, the disclosure provides a method of lowering triglycerides in subject on stable statin therapy and having mean baseline fasting triglyceride level of about 200 mg/dl to less than 500 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ultra-pure EPA, wherein upon administering the composition to the subject daily for a period of about 12 weeks the subject exhibits (a) at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75% lower fasting triglycerides by comparison with a control subject maintained on stable statin therapy without concomitant ultra-pure EPA for a period of about 12 weeks and (b) no increase in serum LDL-C levels compared to baseline, wherein the control subject also has baseline fasting triglycerides of about 200 mg/dl to less than 500 mg/dl.

[0034] In another embodiment, the disclosure provides a method of lowering triglycerides in subject group on stable statin therapy and having mean baseline fasting triglyceride level of about 200 mg/dl to less than 500 mg/dl, the method comprising administering to members of the subject group a pharmaceutical composition comprising about 1 g to about 4 g of ultra-pure EPA, wherein upon administering the composition to the members of the subject group daily for a period of about 12 weeks the subject group exhibits: (a) at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% lower mean fasting

triglycerides and (b) at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45% or at least 50% lower mean serum LDL-C levels by comparison with a control subject group maintained on stable statin therapy without concomitant ultra-pure EPA (optionally with matching placebo) for a period of about 12 weeks, no serum LDL-C increase, no statistically significant serum LDL-C increase, no statistically significant serum LDL-C increase, a serum LDL-C decrease, or the subject group is statistically non- inferior to the control subject group (statin plus optional placebo) in regard to serum LDL-C elevation), wherein the control subject group also has mean baseline fasting triglycerides of about 200 mg/dl to less than 500 mg/dl.

[0035] In another embodiment, the disclosure provides a method of lowering triglycerides in subject group on stable statin therapy and having mean baseline fasting triglyceride level of about 200 mg/dl to less than 500 mg/dl, the method comprising administering to members of the subject group a pharmaceutical composition comprising about 1 g to about 4 g of ultra-pure EPA, wherein upon administering the composition to the members of the subject group daily for a period of about 12 weeks the subject group exhibits (a) at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% lower mean fasting

triglycerides and (b) at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45% or at least 50% lower mean serum LDL-C levels by comparison with a control subject group maintained on stable statin therapy without concomitant ultra-pure EPA (optionally with matching placebo) for a period of about 12 weeks, no serum LDL-C increase, no statistically significant serum LDL-C increase, no statistically significant serum LDL-C increase, a serum LDL-C decrease, or the subject group is statistically non- inferior to the control subject group (statin plus optional placebo) in regard to serum LDL-C elevation), wherein the control subject group also has mean baseline fasting triglycerides of about 200 mg/dl to less than 500 mg/dl.

[0036] In one embodiment, the subject or subject group being treated in accordance with methods of the invention has previously been treated with Lovaza® and has experienced an increase in, or no decrease in, LDL-C levels and/or non-HDL-C levels. In one such embodiment, Lovaza® therapy is discontinued and replaced by a method of the present invention.

[0037] In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline absolute plasma level of free EPA (or mean thereof in the case of a subject group) not greater than about 0.70 nmol/ml, not greater than about 0.65 nmol/ml, not greater than about 0.60 nmol/ml, not greater than about 0.55 nmol/ml, not greater than about 0.50 nmol/ml, not greater than about 0.45 nmol/ml, or not greater than about 0.40 nmol/ml. In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a baseline fasting plasma level (or mean thereof) of free EPA, expressed as a percentage of total free fatty acid, of not more than about 3%, not more than about 2.5%, not more than about 2%, not more than about 1.5%, not more than about 1%, not more than about 0.75%, not more than about 0.5%, not more than about 0.25%, not more than about 0.2% or not more than about 0.15%. In one such embodiment, free plasma EPA and/or total fatty acid levels are determined prior to initiating therapy. [0038] In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline absolute plasma level of total fatty acid (or mean thereof) not greater than about 250 nmol/ml, not greater than about 200 nmol/ml, not greater than about 150 nmol/ml, not greater than about 100 nmol/ml, or not greater than about 50 nmol/ml.

[0039] In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline plasma, serum or red blood cell membrane EPA level not greater than about 70 g/ml, not greater than about 60 g/ml, not greater than about 50 g/ml, not greater than about 40 g/ml, not greater than about 30 μg/ml, or not greater than about 25 μg/ml.

[0040] In another embodiment, methods of the present invention comprise a step of measuring the subject's (or subject group's mean) baseline lipid profile prior to initiating therapy. In another embodiment, methods of the invention comprise the step of identifying a subject or subject group having one or more of the following: baseline non-HDL-C value of about 200 mg/dL to about 400 mg/dL, for example at least about 210 mg/dL, at least about 220 mg/dL, at least about 230 mg/dL, at least about 240 mg/dL, at least about 250 mg/dL, at least about 260 mg/dL, at least about 270 mg/dL, at least about 280 mg/dL, at least about 290 mg/dL, or at least about 300 mg/dL;

baseline total cholesterol value of about 250 mg/dL to about 400 mg/dL, for example at least about 260 mg/dL, at least about 270 mg/dL, at least about 280 mg/dL or at least about 290 mg/dL; baseline vLDL-C value of about 140 mg/dL to about 200 mg/dL, for example at least about 150 mg/dL, at least about 160 mg/dL, at least about 170 mg/dL, at least about 180 mg/dL or at least about 190 mg/dL; baseline HDL-C value of about 10 to about 60 mg/dL, for example not more than about 40 mg/ dl, not more than about 35 mg/dL, not more than about 30 mg/dL, not more than about 25 mg/dL, not more than about 20 mg/dL, or not more than about 15 mg/dL; and/or baseline LDL-C value of about 50 to about 300 mg/dL, for example not less than about 100 mg/dL, not less than about 90 mg/dL, not less than about 80 mg/dL, not less than about 70 mg/dL, not less than about 60 mg/dL or not less than about 50 mg/dL.

[0041] In a related embodiment, upon treatment in accordance with the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about 1 to about 20 weeks, about 1 to about 15 weeks, about 1 to about 12 weeks, about 1 to about 10 weeks, about 1 to about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits one or more of the following outcomes:

[0042] (a) reduced triglyceride levels compared to baseline or placebo control;

[0043] (b) reduced Apo B levels compared to baseline or placebo control;

[0044] (c) increased HDL-C levels compared to baseline or placebo control;

[0045] (d) no increase in LDL-C levels compared to baseline or placebo control;

[0046] (e) a reduction in LDL-C levels compared to baseline or placebo control;

[0047] (f) a reduction in non-HDL-C levels compared to baseline or placebo control;

[0048] (g) a reduction in vLDL levels compared to baseline or placebo control;

[0049] (h) an increase in apo A-I levels compared to baseline or placebo control;

[0050] (i) an increase in apo A-I/apo B ratio compared to baseline or placebo control;

[0051] (j) a reduction in lipoprotein A levels compared to baseline or placebo control;

[0052] (k) a reduction in LDL particle number compared to baseline or placebo control;

[0053] (1) an increase in LDL size compared to baseline or placebo control;

[0054] (m) a reduction in remnant-like particle cholesterol compared to baseline or placebo control;

[0055] (n) a reduction in oxidized LDL compared to baseline or placebo control; [0056] (o) no change or a reduction in fasting plasma glucose (FPG) compared to baseline or placebo control;

[0057] (p) a reduction in hemoglobin Alc (HbAic) compared to baseline or placebo control;

[0058] (q) a reduction in homeostasis model insulin resistance compared to baseline or placebo control;

[0059] (r) a reduction in lipoprotein associated phospholipase A2 compared to baseline or placebo control;

[0060] (s) a reduction in intracellular adhesion molecule- 1 compared to baseline or placebo control;

[0061] (t) a reduction in interleukin-6 compared to baseline or placebo control;

[0062] (u) a reduction in plasminogen activator inhibitor- 1 compared to baseline or placebo control;

[0063] (v) a reduction in high sensitivity C-reactive protein (hsCRP) compared to baseline or placebo control;

[0064] (w) an increase in serum or plasma EPA compared to baseline or placebo control;

[0065] (x) an increase in red blood cell (RBC) membrane EPA compared to baseline or placebo control; and/or

[0066] (y) a reduction or increase in one or more of serum phospholipid and/or red blood cell content of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), arachidonic acid (AA), palmitic acid (PA), staeridonic acid (SA) or oleic acid (OA) compared to baseline or placebo control.

[0067] In one embodiment, upon administering a composition of the invention to a subject, the subject exhibits a decrease in triglyceride levels, an increase in the concentrations of EPA and DPA (n-3) in red blood cells, and an increase of the ratio of EPA:arachidonic acid in red blood cells. In a related embodiment the subject exhibits substantially no or no increase in RBC DHA.

[0068] In one embodiment, methods of the present invention comprise measuring baseline levels of one or more markers set forth in (a) - (y) above prior to dosing the subject or subject group. In another embodiment, the methods comprise administering a composition as disclosed herein to the subject after baseline levels of one or more markers set forth in (a) - (y) are determined, and subsequently taking an additional measurement of said one or more markers.

[0069] In another embodiment, upon treatment with a composition of the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about 1 to about 20 weeks, about 1 to about 15 weeks, about 1 to about 12 weeks, about 1 to about 10 weeks, about 1 to about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits any 2 or more of, any 3 or more of, any 4 or more of, any 5 or more of, any 6 or more of, any 7 or more of, any 8 or more of, any 9 or more of, any 10 or more of, any 1 1 or more of, any 12 or more of, any 13 or more of, any 14 or more of, any 15 or more of, any 16 or more of, any 17 or more of, any 18 or more of, any 19 or more of, any 20 or more of, any 21 or more of, any 22 or more of, any 23 or more of, any 24 or more of, or all 25 of outcomes (a) - (y) described immediately above.

[0070] In another embodiment, upon treatment with a composition of the present invention, the subject or subject group exhibits one or more of the following outcomes:

[0071] (a) an increase of no more than about 15% in triglyceride level, no significant increase in triglyceride level, no increase in triglyceride level, or a reduction in triglyceride level of at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 17%, at least about 19%, at least about 20%, at least about 21%, at least about 25%, at least about 26%, at least about 28%, at least about 29%, at least about 30%, at least about 33%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 62%, or at least about 75% (actual % change or median % change) as compared to baseline or placebo;

[0072] (b) a less than 30% increase, a less than 20% increase, a less than 1 1% increase, a less than 10% increase, a less than 5% increase or no increase in non-HDL- C levels or a reduction in non-HDL-C levels of at least about 1%, at least about 3%, at least about 4%, at least about 5%, at least about 7%, at least about 8%, at least about 9% at least about 10%, at least about 13%, at least about 15%, at least about 18%, at least about 19%, at least about 20%, at least about 25%, at least about 27%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline or placebo;

[0073] (c) substantially no change in HDL-C levels, no change in HDL-C levels, or an increase in HDL-C levels of at least about 0.2%, at least about 0.5%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75%, or a decrease in HDL-C levels of no more than about 3%, no more than about 4%, no more than about 5%, no more than about 6% (actual % change or median % change) as compared to baseline or placebo;

[0074] (d) a less than 60% increase, a less than 50% increase, a less than 40% increase, a less than 30% increase, a less than 20% increase, a less than 10% increase, a less than 7% increase, a less than 5% increase, a less than 4% increase, a less than 3% increase, or a less than 2% increase, no increase in LDL-C levels or a reduction in LDL-C levels of at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 11%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline or placebo; [0075] (e) an increase in Apo B levels of no more than about 5%, or no more than about 3%, no significant increase in Apo B levels, no increase in Apo B levels, or a decrease in Apo B levels of at least about 0.5%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline or placebo;

[0076] (f) a reduction in VLDL levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0077] (g) an increase in apo A-I levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0078] (h) an increase in apo A-I/apo B ratio of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0079] (i) a reduction in lipoprotein (a) levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0080] (j) a reduction in mean LDL particle number of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo; [0081] (k) an increase in mean LDL particle size of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0082] (1) a reduction in remnant-like particle cholesterol of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0083] (m) a reduction in oxidized LDL of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0084] (n) substantially no change, no significant change, or a reduction (e.g. in the case of a diabetic subject) in fasting plasma glucose (FPG) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0085] (o) substantially no change, no significant change or a reduction in hemoglobin Alc (HbAic) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% (actual % change or median % change) compared to baseline or placebo;

[0086] (p) a reduction in homeostasis model index insulin resistance of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo; [0087] (q) a reduction in lipoprotein associated phospholipase A2 of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0088] (r) a reduction in intracellular adhesion molecule- 1 of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0089] (s) a reduction in interleukin-6 of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0090] (t) a reduction in plasminogen activator inhibitor- 1 of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0091] (u) an increase of no more than about 30%, no more than about 26%, or no more than about 15%, no increase in high sensitivity C-reactive protein (hsCRP) or a reduction in hsCRP of at least about 2%, at least about 5%, at least about 7%, at least about 10%, at least about 14%, at least about 15%, at least about 20%, at least about 23%, at least about 25%, at least about 27%, at least about 30%, at least about 35%, at least about 36%, at least about 40%, at least about 45%, at least about 50%, at least about 78%, or at least about 100% (actual % change or median % change) compared to baseline or placebo;

[0092] (v) an increase in serum, plasma and/or RBC EPA of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 100%, at least about 200% or at least about 400% (actual % change or median % change) compared to baseline or placebo;

[0093] (w) an increase in serum phospholipid and/or red blood cell membrane EPA of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50%, at least about 100%, at least about 200%, or at least about 400% (actual % change or median % change) compared to baseline or placebo;

[0094] (x) a reduction or increase in one or more of serum phospholipid and/or red blood cell DHA, DPA, AA, PA and/or OA of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) compared to baseline or placebo; and/or

[0095] (y) a reduction in total cholesterol of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) compared to baseline or placebo.

[0096] In one embodiment, methods of the present invention comprise measuring baseline levels of one or more markers set forth in (a) - (y) prior to dosing the subject or subject group. In another embodiment, the methods comprise administering a composition as disclosed herein to the subject after baseline levels of one or more markers set forth in (a) - (y) are determined, and subsequently taking a second measurement of the one or more markers as measured at baseline for comparison thereto.

[0097] In another embodiment, upon treatment with a composition of the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about 1 to about 20 weeks, about 1 to about 15 weeks, about 1 to about 12 weeks, about 1 to about 10 weeks, about 1 to about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits any 2 or more of, any 3 or more of, any 4 or more of, any 5 or more of, any 6 or more of, any 7 or more of, any 8 or more of, any 9 or more of, any 10 or more of, any 1 1 or more of, any 12 or more of, any 13 or more of, any 14 or more of, any 15 or more of, any 16 or more of, any 17 or more of, any 18 or more of, any 19 or more of, any 20 or more of, any 21 or more of, any 22 or more of, any 23 or more of, any 24 or more of, or all 25 or more of outcomes (a) - (y) described immediately above.

[0098] Parameters (a) - (y) can be measured in accordance with any clinically acceptable methodology. For example, triglycerides, total cholesterol, HDL-C and fasting blood sugar can be sample from serum and analyzed using standard photometry techniques. VLDL-TG, LDL-C and VLDL-C can be calculated or determined using serum lipoprotein fractionation by preparative ultracentrifugation and subsequent quantitative analysis by refractometry or by analytic ultracentrifugal methodology. Apo Al, Apo B and hsCRP can be determined from serum using standard

nephelometry techniques. Lipoprotein (a) can be determined from serum using standard turbidimetric immunoassay techniques. LDL particle number and particle size can be determined using nuclear magnetic resonance (NMR) spectrometry.

Remnants lipoproteins and LDL-phospholipase A2 can be determined from EDTA plasma or serum and serum, respectively, using enzymatic immunoseparation techniques. Oxidized LDL, intercellular adhesion molecule- 1 and interleukin-6 levels can be determined from serum using standard enzyme immunoassay techniques.

These techniques are described in detail in standard textbooks, for example Tietz Fundamentals of Clinical Chemistry, 6th Ed. (Burtis, Ashwood and Borter Eds.), WB Saunders Company.

[0099] In one embodiment, subjects fast for up to 12 hours prior to blood sample collection, for example about 10 hours.

[0100] In another embodiment, the subject being treated is in the highest risk category of Adult Treatment Panel (ATP) III Classification of LDL, Total, and HDL Cholesterol (mg/dL) (e.g. CHD or CHD Risk Equivalents (10-year risk >20%)). In another embodiment, the subject is in the ATP III Multiple (2+) risk factor category. [0101] In one embodiment, the disclosure provides a method of lowering triglycerides in a subject in the highest risk category of Adult Treatment Panel (ATP) III Classification of LDL, Total, and HDL Cholesterol (mg/dL) (e.g. CHD or CHD Risk Equivalents (10-year risk >20%)). In another embodiment, the subject is in the ATP III Multiple (2+) risk factor category. In another embodiment, the method includes a step of identifying a subject in the ATP III Multiple (2+) risk factor category prior to administering ultra-pure E-EPA to the subject.

[0102] In another embodiment, the present invention provides a method of treating or preventing primary hypercholesterolemia and/or mixed dyslipidemia (Fredrickson Types Ila and lib) in a patient in need thereof, comprising administering to the patient one or more compositions as disclosed herein. In a related embodiment, the present invention provides a method of reducing triglyceride levels in a subject or subjects when treatment with a statin or niacin extended-release monotherapy is considered inadequate (Frederickson type IV hyperlipidemia).

[0103] In another embodiment, the present invention provides a method of treating or preventing risk of recurrent nonfatal myocardial infarction in a patient with a history of myocardial infarction, comprising administering to the patient one or more compositions as disclosed herein.

[0104] In another embodiment, the present invention provides a method of slowing progression of or promoting regression of atherosclerotic disease in a patient in need thereof, comprising administering to a subject in need thereof one or more

compositions as disclosed herein.

[0105] In another embodiment, the present invention provides a method of treating or preventing very high serum triglyceride levels (e.g. Types IV and V hyperlipidemia) in a patient in need thereof, comprising administering to the patient one or more compositions as disclosed herein.

[0106] In another embodiment, the present invention provides a method of treating subjects having very high serum triglyceride levels (e.g. greater than 1000 mg/dL or greater than 2000 mg/dL) and that are at risk of developing pancreatitis, comprising administering to the patient one or more compositions as disclosed herein. [0107] In one embodiment, a composition of the invention is administered to a subject in an amount sufficient to provide a daily dose of eicosapentaenoic acid of about 1 mg to about 10,000 mg, 25 about 5000 mg, about 50 to about 3000 mg, about 75 mg to about 2500 mg, or about 100 mg to about 1000 mg, for example about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1100 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1200 mg, about 1225 mg, about 1250 mg, about 1275 mg, about 1300 mg, about 1325 mg, about 1350 mg, about 1375 mg, about 1400 mg, about 1425 mg, about 1450 mg, about 1475 mg, about 1500 mg, about 1525 mg, about 1550 mg, about 1575 mg, about 1600 mg, about 1625 mg, about 1650 mg, about 1675 mg, about 1700 mg, about 1725 mg, about 1750 mg, about 1775 mg, about 1800 mg, about 1825 mg, about 1850 mg, about 1875 mg, about 1900 mg, about 1925 mg, about 1950 mg, about 1975 mg, about 2000 mg, about 2025 mg, about 2050 mg, about 2075 mg, about 2100 mg, about 2125 mg, about 2150 mg, about 2175 mg, about 2200 mg, about 2225 mg, about 2250 mg, about 2275 mg, about 2300 mg, about 2325 mg, about 2350 mg, about 2375 mg, about 2400 mg, about 2425 mg, about 2450 mg, about 2475 mg, about 2500 mg, about 2525 mg, about 2550 mg, about 2575 mg, about 2600 mg, about 2625 mg, about 2650 mg, about 2675 mg, about 2700 mg, about 2725 mg, about 2750 mg, about 2775 mg, about 2800 mg, about 2825 mg, about 2850 mg, about 2875 mg, about 2900 mg, about 2925 mg, about 2950 mg, about 2975 mg, about 3000 mg, about 3025 mg, about 3050 mg, about 3075 mg, about 3100 mg, about 3125 mg, about 3150 mg, about 3175 mg, about 3200 mg, about 3225 mg, about 3250 mg, about 3275 mg, about 3300 mg, about 3325 mg, about 3350 mg, about 3375 mg, about 3400 mg, about 3425 mg, about 3450 mg, about 3475 mg, about 3500 mg, about 3525 mg, about 3550 mg, about 3575 mg, about 3600 mg, about 3625 mg, about 3650 mg, about 3675 mg, about 3700 mg, about 3725 mg, about 3750 mg, about 3775 mg, about 3800 mg, about 3825 mg, about 3850 mg, about 3875 mg, about 3900 mg, about 3925 mg, about 3950 mg, about 3975 mg, about 4000 mg, about 4025 mg, about 4050 mg, about 4075 mg, about 4100 mg, about 4125 mg, about 4150 mg, about 4175 mg, about 4200 mg, about 4225 mg, about 4250 mg, about 4275 mg, about 4300 mg, about 4325 mg, about 4350 mg, about 4375 mg, about 4400 mg, about 4425 mg, about 4450 mg, about 4475 mg, about 4500 mg, about 4525 mg, about 4550 mg, about 4575 mg, about 4600 mg, about 4625 mg, about 4650 mg, about 4675 mg, about 4700 mg, about 4725 mg, about 4750 mg, about 4775 mg, about 4800 mg, about 4825 mg, about 4850 mg, about 4875 mg, about 4900 mg, about 4925 mg, about 4950 mg, about 4975 mg, about 5000 mg, about 5025 mg, about 5050 mg, about 5075 mg, about 5100 mg, about 5125 mg, about 5150 mg, about 5175 mg, about 5200 mg, about 5225 mg, about 5250 mg, about 5275 mg, about 5300 mg, about 5325 mg, about 5350 mg, about 5375 mg, about 5400 mg, about 5425 mg, about 5450 mg, about 5475 mg, about 5500 mg, about 5525 mg, about 5550 mg, about 5575 mg, about 5600 mg, about 5625 mg, about 5650 mg, about 5675 mg, about 5700 mg, about 5725 mg, about 5750 mg, about 5775 mg, about 5800 mg, about 5825 mg, about 5850 mg, about 5875 mg, about 5900 mg, about 5925 mg, about 5950 mg, about 5975 mg, about 6000 mg, about 6025 mg, about 6050 mg, about 6075 mg, about 6100 mg, about 6125 mg, about 6150 mg, about 6175 mg, about 6200 mg, about 6225 mg, about 6250 mg, about 6275 mg, about 6300 mg, about 6325 mg, about 6350 mg, about 6375 mg, about 6400 mg, about 6425 mg, about 6450 mg, about 6475 mg, about 6500 mg, about 6525 mg, about 6550 mg, about 6575 mg, about 6600 mg, about 6625 mg, about 6650 mg, about 6675 mg, about 6700 mg, about 6725 mg, about 6750 mg, about 6775 mg, about 6800 mg, about 6825 mg, about 6850 mg, about 6875 mg, about 6900 mg, about 6925 mg, about 6950 mg, about 6975 mg, about 7000 mg, about 7025 mg, about 7050 mg, about 7075 mg, about 7100 mg, about 7125 mg, about 7150 mg, about 7175 mg, about 7200 mg, about 7225 mg, about 7250 mg, about 7275 mg, about 7300 mg, about 7325 mg, about 7350 mg, about 7375 mg, about 7400 mg, about 7425 mg, about 7450 mg, about 7475 mg, about 7500 mg, about 7525 mg, about 7550 mg, about 7575 mg, about 7600 mg, about 7625 mg, about 7650 mg, about 7675 mg, about 7700 mg, about 7725 mg, about 7750 mg, about 7775 mg, about 7800 mg, about 7825 mg, about 7850 mg, about 7875 mg, about 7900 mg, about 7925 mg, about 7950 mg, about 7975 mg, about 8000 mg, about 8025 mg, about 8050 mg, about 8075 mg, about 8100 mg, about 8125 mg, about 8150 mg, about 8175 mg, about 8200 mg, about 8225 mg, about 8250 mg, about 8275 mg, about 8300 mg, about 8325 mg, about 8350 mg, about 8375 mg, about 8400 mg, about 8425 mg, about 8450 mg, about 8475 mg, about 8500 mg, about 8525 mg, about 8550 mg, about 8575 mg, about 8600 mg, about 8625 mg, about 8650 mg, about 8675 mg, about 8700 mg, about 8725 mg, about 8750 mg, about 8775 mg, about 8800 mg, about 8825 mg, about 8850 mg, about 8875 mg, about 8900 mg, about 8925 mg, about 8950 mg, about 8975 mg, about 9000 mg, about 9025 mg, about 9050 mg, about 9075 mg, about 9100 mg, about 9125 mg, about 9150 mg, about 9175 mg, about 9200 mg, about 9225 mg, about 9250 mg, about 9275 mg, about 9300 mg, about 9325 mg, about 9350 mg, about 9375 mg, about 9400 mg, about 9425 mg, about 9450 mg, about 9475 mg, about 9500 mg, about 9525 mg, about 9550 mg, about 9575 mg, about 9600 mg, about 9625 mg, about 9650 mg, about 9675 mg, about 9700 mg, about 9725 mg, about 9750 mg, about 9775 mg, about 9800 mg, about 9825 mg, about 9850 mg, about 9875 mg, about 9900 mg, about 9925 mg, about 9950 mg, about 9975 mg, about 10,000 mg.

[0108] In another embodiment, any of the methods disclosed herein are used in treatment or prevention of a subject or subjects that consume a traditional Western diet. In one embodiment, the methods of the invention include a step of identifying a subject as a Western diet consumer or prudent diet consumer and then treating the subject if the subject is deemed a Western diet consumer. The term "Western diet" herein refers generally to a typical diet consisting of, by percentage of total calories, about 45% to about 50% carbohydrate, about 35% to about 40% fat, and about 10% to about 15% protein. A Western diet may alternately or additionally be characterized by relatively high intakes of red and processed meats, sweets, refined grains, and desserts, for example more than 50%, more than 60% or more or 70% of total calories come from these sources.

[0109] In another embodiment, any of the methods disclosed herein are used in treatment of a subject or subjects that consume less than (actual or average) about 150 g, less than about 125 g, less than about 100 g, less than about 75 g, less than about 50 g, less than about 45 g, less than about 40 g, less than about 35 g, less than about 30 g, less than about 25 g, less than about 20 g or less than about 15 g of fish per day. [0110] In another embodiment, any of the methods disclosed herein are used in treatment of a subject or subjects that consume less than (actual or average) about 10 g, less than about 9 g, less than about 8 g, less than about 7 g, less than about 6 g, less than about 5 g, less than about 4 g, less than about 3 g, less than about 2 g per day of omega-3 fatty acids from dietary sources.

[0111] In another embodiment, any of the methods disclosed herein are used in treatment of a subject or subjects that consume less than (actual or average) about 2.5 g, less than about 2 g, less than about 1.5 g, less than about 1 g, less than about 0.5 g, less than about 0.25 g, or less than about 0.2 g per day of EPA and DHA (combined) from dietary sources.

[0112] In one embodiment, a composition for use in methods of the invention comprises eicosapentaenoic acid, or a pharmaceutically acceptable ester, derivative, conjugate or salt thereof, or mixtures of any of the foregoing, collectively referred to herein as "EPA." The term "pharmaceutically acceptable" in the present context means that the substance in question does not produce unacceptable toxicity to the subject or interaction with other components of the composition.

[0113] In one embodiment, the EPA comprises all-cis eicosa-5, 8,1 1, 14, 17- pentaenoic acid. In another embodiment, the EPA comprises an eicosapentaenoic acid ester. In another embodiment, the EPA comprises a Ci - C5 alkyl ester of

eicosapentaenoic acid. In another embodiment, the EPA comprises eicosapentaenoic acid ethyl ester, eicosapentaenoic acid methyl ester, eicosapentaenoic acid propyl ester, or eicosapentaenoic acid butyl ester. In another embodiment, the EPA comprises In one embodiment, the EPA comprises all-cis eicosa-5, 8, 1 1, 14, 17 -pentaenoic acid ethyl ester.

[0114] In another embodiment, the EPA is in the form of ethyl-EPA, lithium EPA, mono-, di- or triglyceride EPA or any other ester or salt of EPA, or the free acid form of EPA. The EPA may also be in the form of a 2-substituted derivative or other derivative which slows down its rate of oxidation but does not otherwise change its biological action to any substantial degree. [0115] In another embodiment, EPA is present in a composition useful in accordance with methods of the invention in an amount of about 50 mg to about 5000 mg, about 75 mg to about 2500 mg, or about 100 mg to about 1000 mg, for example about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1100 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1200 mg, about 1225 mg, about 1250 mg, about 1275 mg, about 1300 mg, about 1325 mg, about 1350 mg, about 1375 mg, about 1400 mg, about 1425 mg, about 1450 mg, about 1475 mg, about 1500 mg, about 1525 mg, about 1550 mg, about 1575 mg, about 1600 mg, about 1625 mg, about 1650 mg, about 1675 mg, about 1700 mg, about 1725 mg, about 1750 mg, about 1775 mg, about 1800 mg, about 1825 mg, about 1850 mg, about 1875 mg, about 1900 mg, about 1925 mg, about 1950 mg, about 1975 mg, about 2000 mg, about 2025 mg, about 2050 mg, about 2075 mg, about 2100 mg, about 2125 mg, about 2150 mg, about 2175 mg, about 2200 mg, about 2225 mg, about 2250 mg, about 2275 mg, about 2300 mg, about 2325 mg, about 2350 mg, about 2375 mg, about 2400 mg, about 2425 mg, about 2450 mg, about 2475 mg, about 2500 mg, about 2525 mg, about 2550 mg, about 2575 mg, about 2600 mg, about 2625 mg, about 2650 mg, about 2675 mg, about 2700 mg, about 2725 mg, about 2750 mg, about 2775 mg, about 2800 mg, about 2825 mg, about 2850 mg, about 2875 mg, about 2900 mg, about 2925 mg, about 2950 mg, about 2975 mg, about 3000 mg, about 3025 mg, about 3050 mg, about 3075 mg, about 3100 mg, about 3125 mg, about 3150 mg, about 3175 mg, about 3200 mg, about 3225 mg, about 3250 mg, about 3275 mg, about 3300 mg, about 3325 mg, about 3350 mg, about 3375 mg, about 3400 mg, about 3425 mg, about 3450 mg, about 3475 mg, about 3500 mg, about 3525 mg, about 3550 mg, about 3575 mg, about 3600 mg, about 3625 mg, about 3650 mg, about 3675 mg, about 3700 mg, about 3725 mg, about 3750 mg, about 3775 mg, about 3800 mg, about 3825 mg, about 3850 mg, about 3875 mg, about 3900 mg, about 3925 mg, about 3950 mg, about 3975 mg, about 4000 mg, about 4025 mg, about 4050 mg, about 4075 mg, about 4100 mg, about 4125 mg, about 4150 mg, about 4175 mg, about 4200 mg, about 4225 mg, about 4250 mg, about 4275 mg, about 4300 mg, about 4325 mg, about 4350 mg, about 4375 mg, about 4400 mg, about 4425 mg, about 4450 mg, about 4475 mg, about 4500 mg, about 4525 mg, about 4550 mg, about 4575 mg, about 4600 mg, about 4625 mg, about 4650 mg, about 4675 mg, about 4700 mg, about 4725 mg, about 4750 mg, about 4775 mg, about 4800 mg, about 4825 mg, about 4850 mg, about 4875 mg, about 4900 mg, about 4925 mg, about 4950 mg, about 4975 mg, or about 5000 mg.

[0116] In another embodiment, a composition useful in accordance with the invention contains not more than about 10%, not more than about 9%, not more than about 8%, not more than about 7%, not more than about 6%, not more than about 5%, not more than about 4%, not more than about 3%, not more than about 2%, not more than about 1%, or not more than about 0.5%, by weight, docosahexaenoic acid (DHA), if any. In another embodiment, a composition of the invention contains substantially no docosahexaenoic acid. In still another embodiment, a composition useful in the present invention contains no docosahexaenoic acid and/or derivative thereof.

[0117] In another embodiment, EPA comprises at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, by weight, of all fatty acids present in a composition that is useful in methods of the present invention.

[0118] In one embodiment, a composition of the invention comprises ultra-pure EPA. The term "ultra-pure" as used herein with respect to EPA refers to a

composition comprising at least 95% by weight EPA (as the term "EPA" is defined and exemplified herein). Ultra-pure EPA comprises at least 96% by weight EPA, at least 97% by weight EPA, or at least 98% by weight EPA, wherein the EPA is any form of EPA as set forth herein.

[0119] In another embodiment, a composition useful in accordance with methods of the invention contains less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5% or less than 0.25%, by weight of the total composition or by weight of the total fatty acid content, of any fatty acid other than EPA. Illustrative examples of a "fatty acid other than EPA" include linolenic acid (LA), arachidonic acid (AA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), stearadonic acid (STA), eicosatrienoic acid (ETA) and/or docosapentaenoic acid (DP A). In another embodiment, a composition useful in accordance with methods of the invention contains about 0.1% to about 4%, about 0.5% to about 3%, or about 1% to about 2%, by weight, of total fatty acids other than EPA and/or DHA.

[0120] In another embodiment, a composition useful in accordance with the invention has one or more of the following features: (a) eicosapentaenoic acid ethyl ester represents at least about 96%, at least about 97%, or at least about 98%, by weight, of all fatty acids present in the composition; (b) the composition contains not more than about 4%, not more than about 3%, or not more than about 2%, by weight, of total fatty acids other than eicosapentaenoic acid ethyl ester; (c) the composition contains not more than about 0.6%, not more than about 0.5%, or not more than about 0.4% of any individual fatty acid other than eicosapentaenoic acid ethyl ester; (d) the composition has a refractive index (20 °C) of about 1 to about 2, about 1.2 to about 1.8 or about 1.4 to about 1.5; (e) the composition has a specific gravity (20 °C) of about 0.8 to about 1.0, about 0.85 to about 0.95 or about 0.9 to about 0.92; (e) the composition contains not more than about 20 ppm, not more than about 15 ppm or not more than about 10 ppm heavy metals, (f) the composition contains not more than about 5 ppm, not more than about 4 ppm, not more than about 3 ppm, or not more than about 2 ppm arsenic, and/or (g) the composition has a peroxide value of not more than about 5 meq kg, not more than about 4 meq kg, not more than about 3 meq/kg, or not more than about 2 meq/kg.

[0121] In another embodiment, a composition useful in accordance with the invention comprises, consists of or consists essentially of at least 95% by weight ethyl eicosapentaenoate (EPA-E), about 0.2% to about 0.5% by weight ethyl

octadecatetraenoate (ODTA-E), about 0.05% to about 0.25% by weight ethyl nondecapentaenoate ( DPA-E), about 0.2% to about 0.45% by weight ethyl arachidonate (AA-E), about 0.3% to about 0.5% by weight ethyl eicosatetraenoate (ETA-E), and about 0.05% to about 0.32% ethyl heneicosapentaenoate (HPA-E). In another embodiment, the composition is present in a capsule shell.

[0122] In another embodiment, compositions useful in accordance with the invention comprise, consist essential of, or consist of at least 95%, 96% or 97%, by weight, ethyl eicosapentaenoate, about 0.2% to about 0.5% by weight ethyl octadecatetraenoate, about 0.05% to about 0.25% by weight ethyl nondecapentaenoate, about 0.2% to about 0.45% by weight ethyl arachidonate, about 0.3% to about 0.5% by weight ethyl eicosatetraenoate, and about 0.05% to about 0.32% ethyl

heneicosapentaenoate. Optionally, the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, DHA or derivative thereof such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative thereof such as ethyl-DHA. The composition further optionally comprises one or more antioxidants (e.g. tocopherol) or other impurities in an amount of not more than about 0.5% or not more than 0.05%. In another embodiment, the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol. In another embodiment, about 500 mg to about 1 g of the composition is provided in a capsule shell.

[0123] In another embodiment, compositions useful in accordance with the invention comprise, consist essential of, or consist of at least 96% by weight ethyl eicosapentaenoate, about 0.22% to about 0.4% by weight ethyl octadecatetraenoate, about 0.075% to about 0.20% by weight ethyl nondecapentaenoate, about 0.25% to about 0.40% by weight ethyl arachidonate, about 0.3% to about 0.4% by weight ethyl eicosatetraenoate and about 0.075% to about 0.25% ethyl heneicosapentaenoate.

Optionally, the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, DHA or derivative thereof such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative thereof such as ethyl-DHA. The composition further optionally comprises one or more antioxidants (e.g. tocopherol) or other impurities in an amount of not more than about 0.5% or not more than 0.05%. In another embodiment, the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol. In another embodiment, the invention provides a dosage form comprising about 500 mg to about 1 g of the foregoing composition in a capsule shell. In one embodiment, the dosage form is a gel or liquid capsule and is packaged in blister packages of about 1 to about 20 capsules per sheet.

[0124] In another embodiment, compositions useful in accordance with the invention comprise, consist essential of, or consist of at least 96%, 97% or 98%, by weight, ethyl eicosapentaenoate, about 0.25% to about 0.38% by weight ethyl octadecatetraenoate, about 0.10% to about 0.15% by weight ethyl nondecapentaenoate, about 0.25% to about 0.35% by weight ethyl arachidonate, about 0.31% to about 0.38% by weight ethyl eicosatetraenoate, and about 0.08% to about 0.20% ethyl heneicosapentaenoate. Optionally, the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, DHA or derivative thereof such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative thereof such as ethyl-DHA. The composition further optionally comprises one or more antioxidants (e.g. tocopherol) or other impurities in an amount of not more than about 0.5% or not more than 0.05%. In another embodiment, the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol. In another embodiment, the invention provides a dosage form comprising about 500 mg to about 1 g of the foregoing composition in a capsule shell.

[0125] In another embodiment, a composition as described herein is administered to a subject once or twice per day. In another embodiment, 1, 2, 3 or 4 capsules, each containing about 1 g of a composition as described herein, are administered to a subject daily. In another embodiment, 1 or 2 capsules, each containing about 1 g of a composition as described herein, are administered to the subject in the morning, for example between about 5 am and about 1 1 am, and 1 or 2 capsules, each containing about 1 g of a composition as described herein, are administered to the subject in the evening, for example between about 5 pm and about 11 pm.

[0126] In one embodiment, a subject being treated in accordance with methods of the invention is not otherwise on lipid-altering therapy, for example statin, fibrate, niacin and/or ezetimibe therapy. [0127] In another embodiment, compositions useful in accordance with methods of the invention are orally deliverable. The terms "orally deliverable" or "oral administration" herein include any form of delivery of a therapeutic agent or a composition thereof to a subject wherein the agent or composition is placed in the mouth of the subject, whether or not the agent or composition is swallowed. Thus "oral administration" includes buccal and sublingual as well as esophageal administration. In one embodiment, the composition is present in a capsule, for example a soft gelatin capsule.

[0128] A composition for use in accordance with the invention can be formulated as one or more dosage units. The terms "dose unit" and "dosage unit" herein refer to a portion of a pharmaceutical composition that contains an amount of a therapeutic agent suitable for a single administration to provide a therapeutic effect. Such dosage units may be administered one to a plurality (i.e. 1 to about 10, 1 to 8, 1 to 6, 1 to 4 or 1 to 2) of times per day, or as many times as needed to elicit a therapeutic response.

[0129] In another embodiment, the invention provides use of any composition described herein for treating moderate to severe hypertriglyceridemia in a subject in need thereof, comprising: providing a subject having a fasting baseline triglyceride level of about 500 mg/dL to about 1500 mg/dL and administering to the subject a pharmaceutical composition as described herein. In one embodiment, the composition comprises about 1 g to about 4 g of eicosapentaenoic acid ethyl ester, wherein the composition contains substantially no docosahexaenoic acid.

[0130] In one embodiment, compositions of the invention, upon storage in a closed container maintained at room temperature, refrigerated (e.g. about 5 to about 5 -10 °C) temperature, or frozen for a period of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, or 12 months, exhibit at least about 90%, at least about 95%, at least about 97.5%, or at least about 99% of the active ingredient(s) originally present therein.

[0131] In one embodiment, the invention provides use of a composition as described herein in manufacture of a medicament for treatment of any of a

cardiovascular-related disease. In another embodiment, the subject is diabetic. [0132] In one embodiment, a composition as set forth herein is packaged together with instructions for using the composition to treat a cardiovascular disorder.

EXAMPLES

Example 1 : MARINE Study.

[0133] A multi-center, placebo-controlled randomized, double-blind, 12-week study with an open-label extension was performed to evaluate the efficacy and safety of AMRlOl in patients with fasting triglyceride levels >500 mg/dL. The primary objective of the study was to determine the efficacy of AMRlOl 2 g daily and 4 g daily, compared to placebo, in lowering fasting TG levels in patients with fasting TG levels >500 mg/dL and <1500 mg/dL (>5.65 mmol/L and <16.94 mmol/L).

[0134] The secondary objectives of this study were the following:

• To determine the safety and tolerability of AMRlOl 2 g daily and 4 g daily;

• To determine the effect of AMRlOl on lipid and apolipoprotein profiles;

• To determine the effect of AMRlOl on low-density lipoprotein (LDL) particle number and size;

• To determine the effect of AMRlOl on oxidized LDL;

• To determine the effect of AMRlOl on fasting plasma glucose (FPG) and hemoglobin Alc (HbAic);

• To determine the effect of AMRlOl on insulin resistance;

• To determine the effect of AMRlOl on high-sensitivity C-reactive protein (hsCRP);

• To determine the effects of AMRlOl 2 g daily and 4 g daily on the incorporation of fatty acids into red blood cell membranes and into plasma phospholipids;

• To explore the relationship between baseline fasting TG levels and the reduction in fasting TG levels; and • To explore the relationship between an increase in red blood cell membrane eicosapentaenoic acid (EPA) concentrations and the reduction in fasting TG levels.

[0135] The population for this study was men and women (women of childbearing potential will need to be on contraception or practice abstinence) > 18 years of age with a body mass index <45 kg/m2 who were not on lipid-altering therapy or were currently on lipid-altering therapy. Patients currently on statin therapy (with or without ezetimibe) were evaluated by the investigator as to whether this therapy can be safely discontinued at screening, or if it should be continued. If statin therapy (with or without ezetimibe) was to be continued, dose(s) must have been stable for >4 weeks prior to randomization. Patients taking non-statin, lipid-altering medications (niacin >200 mg/day, fibrates, fish oil, other products containing omega-3 fatty acids, or other herbal products or dietary supplements with potential lipid-altering effects), either alone or in combination with statin therapy (with or without ezetimibe), must have been able to safely discontinue non-statin, lipid-altering therapy at screening.

[0136] Approximately 240 patients were randomized at approximately 50 centers in North America, South America, Central America, Europe, India, and South Africa. The study was a 58- to 60-week, Phase 3, multi-center study consisting of 3 study periods: (1) A 6- to 8-week screening period that included a diet and lifestyle stabilization and washout period and a TG qualifying period; (2) A 12-week, double- blind, randomized, placebo-controlled treatment period; and (3) A 40-week, open- label, extension period.

[0137] During the screening period and double-blind treatment period, all visits were to be within ±3 days of the scheduled time. During the open-label extension period, all visits were/are to be within ±7 days of the scheduled time. The screening period included a 4- or 6-week diet and lifestyle stabilization period and washout period followed by a 2-week TG qualifying period. Dose(s) must be stable for >4 weeks prior to randomization. [0138] The screening visit (Visit 1) occurred for all patients at either 6 weeks (for patients not on lipid-altering therapy at screening or for patients who did not need to discontinue their current lipid-altering therapy) or 8 weeks (for patients who required washout of their then-current lipid-altering therapy at screening) before randomization, as follows:

[0139] Patients who did not require a washout: The screening visit occurred at Visit 1 (Week -6). Eligible patients entered a 4-week diet and lifestyle stabilization period. At the screening visit, all patients received counseling regarding the importance of the National Cholesterol Education Program (NCEP) Therapeutic Lifestyle Changes (TLC) diet and received instructions on how to follow this diet. Patients who required a washout: The screening visit occurred at Visit 1 (Week -8). Eligible patients began a 6-week washout period at the screening visit. Patients received counseling regarding the NCEP TLC diet and received instructions on how to follow this diet. Site personnel contacted patients who did not qualify for participation based on screening laboratory test results to instruct them to resume their prior lipid-altering medications.

[0140] At the end of the 4-week diet and lifestyle stabilization period or the 6-week diet and stabilization and washout period, eligible patients entered the 2-week TG qualifying period and had their fasting TG level measured at Visit 2 (Week -2) and Visit 3 (Week -1). Eligible patients must have had an average fasting TG level >500 mg/dL and <1500 mg/dL (>5.65 mmol/L and <16.94 mmol/L) to enter the 12-week double-blind treatment period. The TG level for qualification was based on the average (arithmetic mean) of the Visit 2 (Week -2) and Visit 3 (Week -1) values. If a patient's average TG level from Visit 2 and Visit 3 fell outside the required range for entry into the study, an additional sample for fasting TG measurement was collected 1 week later at Visit 3.1. If a third sample was collected at Visit 3.1, entry into the study was based on the average (arithmetic mean) of the values from Visit 3 and Visit 3.1.

[0141] After confirmation of qualifying fasting TG values, eligible patients entered a 12-week, randomized, double-blind treatment period. At Visit 4 (Week 0), patients were randomly assigned to 1 of the following treatment groups: • AMRlOl 2 g daily,

• AMRlOl 4 g daily, or

• Placebo.

[0142] During the double-blind treatment period, patients returned to the site at Visit 5 (Week 4), Visit 6 (Week 1 1), and Visit 7 (Week 12) for efficacy and safety evaluations.

[0143] Patients who completed the 12-week double-blind treatment period were eligible to enter a 40-week, open-label, extension period at Visit 7 (Week 12). All patients received open-label AMRlOl 4 g daily. From Visit 8 (Week 16) until the end of the study, changes to the lipid-altering regimen were permitted (e.g., initiating or raising the dose of statin or adding non-statin, lipid-altering medications to the regimen), as guided by standard practice and prescribing information. After Visit 8 (Week 16), patients returned to the site every 12 weeks until the last visit at Visit 11 (Week 52).

[0144] Eligible patients were randomly assigned at Visit 4 (Week 0) to receive orally AMRlOl 2 g daily, AMRlOl 4 g daily, or placebo for the 12-week double-blind treatment period. AMRlOl was provided in 1 g liquid-filled, oblong, gelatin capsules. The matching placebo capsule was filled with light liquid paraffin and contained 0 g of AMRlOl . During the double-blind treatment period, patients took 2 capsules

(AMRlOl or matching placebo) in the morning and 2 in the evening for a total of 4 capsules per day. Patients in the AMRlOl 2 g/day treatment group received 1 AMRlOl 1 g capsule and 1 matching placebo capsule in the morning and in the evening. Patients in the AMRlOl 4 g/day treatment group received 2 AMRlOl 1 g capsules in the morning and evening.

[0145] Patients in the placebo group received 2 matching placebo capsules in the morning and evening. During the extension period, patients received open-label AMRlOl 4 g daily. Patients took 2 AMRlOl 1 g capsules in the morning and 2 in the evening. [0146] The primary efficacy variable for the double-blind treatment period was percent change in TG from baseline to Week 12 endpoint. The secondary efficacy variables for the double-blind treatment period included the following:

• Percent changes in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), calculated low-density lipoprotein cholesterol (LDL-C), calculated non- high-density lipoprotein cholesterol (non-HDL-C), and very low-density lipoprotein cholesterol (VLDL-C) from baseline to Week 12 endpoint;

• Percent change in very low-density lipoprotein TG from baseline to Week 12;

• Percent changes in apolipoprotein A-I (apo A-I), apolipoprotein B (apo B), and apo A-Lapo B ratio from baseline to Week 12;

• Percent changes in lipoprotein(a) from baseline to Week 12 (selected sites only);

• Percent changes in LDL particle number and size, measured by nuclear magnetic resonance, from baseline to Week 12 (selected sites only);

• Percent change in remnant-like particle cholesterol from baseline to Week 12 (selected sites only);

• Percent change in oxidized LDL from baseline to Week 12 (selected sites only);

• Changes in FPG and HbAic from baseline to Week 12;

• Change in insulin resistance, as assessed by the homeostasis model index insulin resistance, from baseline to Week 12;

• Percent change in lipoprotein associated phospholipase A2 from baseline to Week 12 (selected sites only);

• Change in intracellular adhesion molecule- 1 from baseline to Week 12 (selected sites only);

• Change in interleukin-6 from baseline to Week 12 (selected sites only);

• Change in plasminogen activator inhibitor- 1 from baseline to Week 12 (selected sites only);

• Change in hsCRP from baseline to Week 12 (selected sites only);

• Change in serum phospholipid EPA content from baseline to Week 12;

• Change in red blood cell membrane EPA content from baseline to Week 12; and • Change in serum phospholipid and red blood cell membrane content in the following fatty acids from baseline to Week 12: docosapentaenoic acid, docosahexaenoic acid, arachidonic acid, palmitic acid, stearic acid, and oleic acid.

[0147] The efficacy variable for the open-label extension period was percent change in fasting TG from extension baseline to end of treatment. Safety assessments included adverse events, clinical laboratory measurements (chemistry, hematology, and urinalysis), 12-lead electrocardiograms (ECGs), vital signs, and physical examinations

[0148] For TG, TC, HDL-C, calculated LDL-C, calculated non-HDL-C, and VLDL-C, baseline was defined as the average of Visit 4 (Week 0) and the preceding lipid qualifying visit (either Visit 3 [Week -1] or if it occurs, Visit 3.1) measurements. Baseline for all other efficacy parameters was the Visit 4 (Week 0) measurement.

[0149] For TC, HDL-C, calculated LDL-C, calculated non-HDL-C, and VLDL-C, Week 12 endpoint was defined as the average of Visit 6 (Week 1 1) and Visit 7 (Week 12) measurements. Week 12 endpoint for all other efficacy parameters was the Visit 7 (Week 12) measurement.

[0150] The primary efficacy analysis was performed using a 2-way analysis of covariance (ANCOVA) model with treatment as a factor and baseline TG value as a covariate. The least-squares mean, standard error, and 2-tailed 95% confidence interval for each treatment group and for each comparison was estimated. The same 2-way ANCOVA model was used for the analysis of secondary efficacy variables.

[0151] The primary analysis was repeated for the per-protocol population to confirm the robustness of the results for the intent-to-treat population.

[0152] The primary efficacy variable was the percent change in fasting TG levels from baseline to Week 12. A sample size of 69 completed patients per treatment group provided >90% power to detect a difference of 30% between AMR101 and placebo in percent change from baseline in fasting TG levels, assuming a standard deviation of 45% in TG measurements and a significance level of p <0.01. To accommodate a 15% drop-out rate from randomization to completion of the double-blind treatment period, a total of 240 randomized patients were planned (80 patients per treatment group).

[0153] Effects of AMR101 in the subset of patients having metabolic syndrome (n=204) compared to placebo are summarized in Table 1. Briefly, administration of 4 g per day of AMR101 significantly reduced blood levels of triglycerides, non-HDL cholesterol, apolipoprotein B, and C-reactive protein ("CRP"), without significantly increasing LDL-C.

Table 1. Changes in Selected Plasma Lipid Parameters vs. Placebo

Figure imgf000041_0001

[0154] As shown in Table 2, the CRP-reducing effects were significant for metabolic syndrome patients on statin therapy, and also for metabolic syndrome patients who did not receive a statin.

Table 2. Changes in CRP vs. Placebo

Figure imgf000041_0002

[0155] Table 3 provides median changes for various endpoints from baseline to week 12 compared to placebo. FIG. 1A shows median percent change compared to baseline from baseline to week 12 for subjects having metabolic syndrome and baseline triglycerides of at least 500 mg/dl and no more than about 2000 mg/dl who receive 4 g per day of a composition according to the present disclosure.

[0156] FIG. IB shows median percent change compared to baseline from baseline to week 12 for subjects having metabolic syndrome and baseline triglycerides of at least 500 mg/dl and no more than about 2000 mg/dl who receive 2 g per day of a composition according to the present disclosure.

[0157] These data show that, in subjects having very high triglycerides and metabolic syndrome, ethyl eicosapentaenoate administered at about 4 g per day improved lipid levels and also reduced hsCRP (a known marker for CVD risk) compared to placebo.

[0158] These data also show that, in subjects having very high triglycerides and metabolic syndrome, numerical reductions in hsCRP were greater in subjects receiving a statin compared to those not on statin therapy.

Table 3. Median Changes in hsCRP and Other End Points in Subjects with Metabolic Syndrome.

Figure imgf000043_0001

LEGAL123989078.1 42

Example 2: ANCHOR Study.

[0159] A multi-center, placebo-controlled, randomized, double-blind, 12-week study was performed to evaluate the efficacy and safety of >96% E-EPA in patients with fasting triglyceride levels > 200 mg/dl and < 500 mg/dl despite statin therapy (the mean of two qualifying entry values needed to be > 185 mg/dl and at least one of the values needed to be > 200 mg/dl). The primary objective of the study was to determine the efficacy of >96% E-EPA 2 g daily and 4 g daily, compared to placebo, in lowering fasting TG levels in patients with high risk for cardiovascular disease and with fasting TG levels

>200 mg/dL and <500 mg/dL, despite treatment to LDL-C goal on statin therapy.

[0160] The secondary objectives of this study were the following:

• To determine the safety and tolerability of >96% E-EPA 2 g daily and 4 g daily;

• To determine the effect of >96% E-EPA on lipid and apolipoprotein profiles

including total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL- C), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and very high density lipoprotein cholesterol (VHDL-C);

• To determine the effect of >96% E-EPA ( on lipoprotein associated phospholipase A2 (Lp-PLA2) from baseline to week 12;

• To determine the effect of >96% E-EPA on low-density lipoprotein (LDL) particle number and size;

• To determine the effect of >96% E-EPA on oxidized LDL;

• To determine the effect of >96% E-EPA on fasting plasma glucose (FPG) and

hemoglobin Aic (HbAic);

• To determine the effect of >96% E-EPA on insulin resistance; • To determine the effect of >96% E-EPA on high-sensitivity C-reactive protein (hsCRP);

• To determine the effects of >96% E-EPA 2 g daily and 4 g daily on the incorporation of fatty acids into red blood cell membranes and into plasma phospholipids;

• To explore the relationship between baseline fasting TG levels and the reduction in fasting TG levels; and

• To explore the relationship between changes of fatty acid concentrations in plasma and red blood cell membranes, and the reduction in fasting TG levels.

[0161] The population for this study was men and women >18 years of age with a body mass index < 45 kg/m2 with fasting TG levels greater than or equal to 200 mg/dl and less than 500 mg/dl and on a stable does of statin therapy (with or without ezetimibe). The statin was atorvostatin, rosuvastatin or simvastatin. The dose of statin must have been stable for > 4 weeks prior to the LDL-C/TG baseline qualifying measurement for randomization. The statin dose was optimized such that the patients are at their LDL-C goal at the LDL-C/TG baseline qualifying measurements. The same statin at the same dose was continued until the study ended.

[0162] Patients taking any additional non- statin, lipid-altering medications (niacin >200 mg/day, fibrates, fish oil, other products containing omega-3 fatty acids, or other herbal products or dietary supplements with potential lipid-altering effects), either alone or in combination with statin therapy (with or without ezetimibe), must have been able to safely discontinue non-statin, lipid-altering therapy at screening.

[0163] Patients at high risk for CVD, i.e., patients with clinical coronary heart disease (CHD) or clinical CHD risk equivalents (10-year risk >20%) as defined in the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) Guidelines were eligible to participate in this study. Those included patients with any of the following criteria: (1) Known CVD, either clinical coronary heart disease (CHD), symptomatic carotid artery disease (CAD), peripheral artery disease (PAD) or abdominal aortic aneurism; or (2) Diabetes Mellitus (Type 1 or 2).

[0164] Approximately 702 patients were randomized at approximately 80 centers in the U.S. The study was a 18- to 20-week, Phase 3, multi-center study consisting of 2 study periods: (1) A 6- to 8-week screening period that included a diet and lifestyle stabilization, a non-statin lipid-altering treatment washout, and an LDL-C and TG qualifying period and (2) A 12-week, double-blind, randomized, placebo-controlled treatment period.

[0165] During the screening period and double -blind treatment period, all visits were within ±3 days of the scheduled time. All patients continued to take the statin product (with or without ezetimibe) at the same dose they were taking at screening throughout their participation in the study.

[0166] The 6- to 8-week screening period included a diet and lifestyle stabilization, a non-statin lipid-altering treatment washout, and an LDL-C and TG qualifying period. The screening visit (Visit 1) occurred for all patients at either 6 weeks (for patients on stable statin therapy [with or without ezetimibe] at screening) or 8 weeks (for patients who will require washout of their current non-statin lipid-altering therapy at screening) before randomization, as follows:

• Patients who did not require a washout: The screening visit occurred at Visit 1 (Week -6). Eligible patients entered a 4-week diet and lifestyle stabilization period. At the screening visit, all patients received counseling regarding the importance of the National Cholesterol Education Program (NCEP) Therapeutic Lifestyle Changes (TLC) diet and received basic instructions on how to follow this diet.

• Patients who required a washout: The screening visit occurred at Visit 1 (Week -8).

Eligible patients began a 6-week washout period at the screening visit (i.e. 6 weeks washout before the first LDL-C/TG qualifying visit). Patients received counseling regarding the NCEP TLC diet and received basic instructions on how to follow this diet. Site personnel contacted patients who did not qualify for participation based on screening laboratory test results to instruct them to resume their prior lipid-altering medications.

[0167] At the end of the 4-week diet and lifestyle stabilization period or the 6-week diet and stabilization and washout period, eligible patients entered the 2-week LDL-C and TG qualifying period and had their fasting LDL-C and TG levels measured at Visit 2 (Week -2) and Visit 3 (Week -1). Eligible patients must have had an average fasting LDL-C level >40 mg/dL and <100 mg/dL and an average fasting TG level >200 mg/dL and <500 mg/dL to enter the 12-week double-blind treatment period. The LDL-C and TG levels for qualification were based on the average (arithmetic mean) of the Visit 2 (Week - 2) and Visit 3 (Week -1) values. If a patient's average LDL-C and/or TG levels from Visit 2 and Visit 3 fell outside the required range for entry into the study, an additional fasting lipid profile was collected 1 week later at Visit 3.1. If a third sample was collected at Visit 3.1, entry into the study was based on the average (arithmetic mean) of the values from Visit 3 and Visit 3.1.

[0168] After confirmation of qualifying fasting LDL-C and TG values, eligible patients entered a 12-week, randomized, double-blind treatment period. At Visit 4 (Week 0), patients were randomly assigned to 1 of the following treatment groups:

>96% E-EPA 2 g daily,

>96% E-EPA 4 g daily,

Placebo.

[0169] 226 to 234 patients per treatment group were randomized in this study.

Stratification was by type of statin (atorvastatin, rosuvastatin or simvastatin), the presence of diabetes, and gender. [0170] During the double-blind treatment period, patients returned to the site at Visit 5 (Week 4), Visit 6 (Week 11), and Visit 7 (Week 12) for efficacy and safety evaluations.

[0171] Eligible patients were randomly assigned at Visit 4 (Week 0) to receive orally >96% E-EPA 2 g daily, >96% E-EPA 4 g daily, or placebo.

[0172] >96% E-EPA was provided in 1 g liquid-filled, oblong, gelatin capsules. The matching placebo capsule was filled with light liquid paraffin and contained 0 g of >96% E-EPA. >96% E-EPA capsules were to be taken with food (i.e. with or at the end of a meal).

[0173] During the double-blind treatment period, patients were to take 2 capsules (>96% E-EPA or matching placebo) in the morning and 2 capsules in the evening for a total of 4 capsules per day.

• Patients in the >96% E-EPA 2 g/day treatment group received 1 >96% E-EPA 1 g capsule and 1 matching placebo capsule in the morning and in the evening.

• Patients in the >96% E-EPA 4 g/day treatment group received 2 >96% E-EPA 1 g capsules in the morning and evening.

[0174] Patients in the placebo group received 2 matching placebo capsules in the morning and evening.

[0175] The primary efficacy variable for the double-blind treatment period was percent change in TG from baseline to Week 12 endpoint. The secondary efficacy variables for the double-blind treatment period included the following:

• Percent changes in total cholesterol (TC), high-density lipoprotein cholesterol (HDL- C), LDL-C, calculated non-HDL-C, and very low-density lipoprotein cholesterol (VLDL-C) from baseline to Week 12 endpoint;

• Percent change in very low-density lipoprotein TG from baseline to Week 12; • Percent changes in apolipoprotein A-I (apo A-I), apolipoprotein B (apo B), and apo A-I/apo B ratio from baseline to Week 12;

• Percent changes in lipoprotein(a) from baseline to Week 12;

• Percent changes in LDL particle number and size, measured by nuclear magnetic resonance, from baseline to Week 12;

• Percent change in remnant- like particle cholesterol from baseline to Week 12;

• Percent change in oxidized LDL from baseline to Week 12;

• Changes in FPG and HbAic from baseline to Week 12;

• Change in insulin resistance, as assessed by the homeostasis model index insulin resistance, from baseline to Week 12;

• Percent change in lipoprotein associated phospholipase A2 (Lp-PLA2) from baseline to Week 12;

• Change in intracellular adhesion molecule- 1 from baseline to Week 12;

• Change in interleukin-2 from baseline to Week 12;

• Change in plasminogen activator inhibitor- 1 from baseline to Week 12. Note: this parameter will only be collected at sites with proper storage conditions;

• Change in hsCRP from baseline to Week 12; and

• Change in plasma concentration and red blood cell membrane content of fatty acid from baseline to Week 12 including EPA, docosapentaenoic acid (DP A), docosahexaenoic acid (DHA), arachidonic acid (AA), dihomo-y-linolenic acid (DGLA), the ratio of EPA/AA, ratio of oleic acid/stearic acid (OA/SA), and the ratio of total omega-3 acids over total omega-6 acids.

[0176] Safety assessments included adverse events, clinical laboratory measurements (chemistry, hematology, and urinalysis), 12-lead electrocardiograms (ECGs), vital signs, and physical examinations. [0177] For TG, TC, HDL-C, LDL-C, calculated non-HDL-C, and VLDL-C, baseline was defined as the average of Visit 4 (Week 0) and the preceding lipid qualifying visit (either Visit 3 [Week -1] or if it occurs, Visit 3.1) measurements. Baseline for all other efficacy parameters was the Visit 4 (Week 0) measurement.

[0178] For TG, TC, HDL-C, LDL-C, calculated non-HDL-C, and VLDL-C, Week 12 endpoint was defined as the average of Visit 6 (Week 11) and Visit 7 (Week 12) measurements.

[0179] Week 12 endpoint for all other efficacy parameters were the Visit 7 (Week 12) measurement.

[0180] The primary efficacy analysis was performed using a 2-way analysis of covariance (ANCOVA) model with treatment as a factor and baseline TG value as a covariate. The least-squares mean, standard error, and 2-tailed 95% confidence interval for each treatment group and for each comparison were estimated. The same 2-way ANCOVA model was used for the analysis of secondary efficacy variables.

[0181] The primary analysis was repeated for the per-protocol population to confirm the robustness of the results for the intent-to-treat population.

[0182] Non-inferiority tests for percent change from baseline in LDL-C were performed between >96% E-EPA doses and placebo using a non-inferiority margin of 6% and a significant level at 0.05.

[0183] For the following key secondary efficacy parameters, treatment groups were compared using Dunnett's test to control the Type 1 error rate: TC, LDL-C, HDL-C, non- HDL-C, VLDL-C, Lp-PLA2, and apo B. For the remaining secondary efficacy parameters, Dunnett's test was be used and the ANCOVA output were considered descriptive.

[0184] The evaluation of safety was based primarily on the frequency of adverse events, clinical laboratory assessments, vital signs, and 12-lead ECGs. The primary efficacy variable is the percent change in fasting TG levels from baseline to Week 12. A sample size of 194 completed patients per treatment group provided 90.6% power to detect a difference of 15% between >96% E-EPA and placebo in percent change from baseline in fasting TG levels, assuming a standard deviation of 45% in TG measurements and a significance level of p <0.05.

[0185] Previous data on fasting LDL-C show a difference in percent change from baseline of 2.2%, with a standard deviation of 15%, between study drug and placebo. A sample size of 194 completed patients per treatment group provided 80% power to demonstrate non-inferiority (p <0.05, one-sided) of the LDL-C response between >96% E- EPA 4 g daily and placebo, within a 6% margin. To accommodate a 10% drop-out rate from randomization to completion of the double-blind treatment period, a total of 648 randomized patients was planned (216 patients per treatment group); 702 subjects were randomized, as further described below.

Results

[0186] Of the 702 randomized subjects, 687 were in the intent-to-treat ("ITT") population as follows:

Ultra-pure EPA, 4 g/day: 226 subjects

Ultra-pure EPA, 2 g/day: 234 subjects

Placebo: 227 subjects

[0187] Lipids were extracted from plasma and red blood cell ("RBC") suspensions and converted into fatty acid methyl esters for analysis using a standard validated gas chromatography/flame ionization detection method. Fatty acid parameters were compared between EPA treatment groups and placebo using an ANCOVA model with treatment, gender, type of statin therapy, and presence of diabetes as factors, and the baseline parameter value as a covariate. LSMs, SEs, and 2-tailed 95% confidence intervals for each treatment group and for each comparison were determined. Subpopulation Analysis: Subjects Having Metabolic Syndrome

[0188] Metabolic Syndrome is typically diagnosed based on many cardiovascular disease (CVD) risk factors, including increased waist circumference and high triglyceride levels. Increased adiposity may promote an increase in C-reactive protein (CRP), which is also a CVD risk factor. Statins are known to reduce CRP, but prior reports of

eicosapentaenoic acid (EPA) combined with docosahexaenoic acid (DHA) on CRP are inconsistent.

[0189] Out of the 687 ITT subjects in this study, 94% (645) had metabolic syndrome. For this subgroup, administration of 4 g per day of E-EPA significantly reduced triglycerides, non-HDL-C, apolipoprotein B, LDL-C and CRP compared to placebo, as shown in Table 4:

Table 4. Change in Lipid levels in Subjects Having Metabolic Syndrome.

Figure imgf000052_0001

[0190] Median changes in select end points are shown for subjects administered 2 g per day and 4 g per day of E-EPA in Table 5 and corresponding FIG. 2.

[0191] These data also show that, in subjects having metabolic syndrome and high triglycerides (e.g., baseline TGs of about 200 mg/dL to less than 500 mg/dL) despite statin therapy, numerical reductions in hsCRP were significantly greater in subjects receiving 4 g/day of >96%> E-EPA compared to subjects receiving placebo. 88896-8060.US02

Table 5. Median Changes from Baseline to Week 12 in hsCRP and Other End Points in Subjects with Metabolic Syndrome.

Figure imgf000053_0001

LEGAL123989078.1

Example 3: Improvement of Cognitive Performance in Subjects with Age-Associated Memory Impairment.

[0192] A single-center, 6-week, double-blind, randomizes, parallel-group, placebo- controlled, dose-ranging pilot study was performed to evaluate the efficacy, tolerability, and safety of >96% ethyl-EPA in subjects with subjective and objective memory impairment according to generally accepted criteria for Age-Associated Memory Impairment ("AAMI"). The primary objective of the study was to determine the effect of >96% ethyl-EPA 1 g, 2 g, and 4 g daily, compared to placebo, on cognitive performance in subjects with AAMI.

[0193] The secondary objectives of this study were the following:

1. To determine the effect of >96% E-EPA on the following tests in the computerized cognitive battery:

• Continuity of attention tasks;

• Quality of working memory tasks;

• Quality of episodic memory tasks; and

• Speed of attention tasks;

2. To determine the safety and tolerability of >96% E-EPA from routine clinical laboratory tests, adverse events ("AE") monitoring, and vital signs; and

3. To determine the potential dose-effect relationship of >96% E-EPA on the cognitive endpoints by measurement of essential fatty acids in plasma and red blood cell membranes.

[0194] The population for this study was men and women between ages 50 and 70 with self-reported complaints of memory loss, subjective and objective cognitive impairment with a score of at least one standard deviation below that of the mean for age-matched elderly population as determined by the total score of between 13 and 20 from the Paired Associated Learning ("PAL") subset of the Wechsler Memory Scale, evidence of adequate intellectual function as determined by a scaled score of at least 9 (raw score of at least 32) on the Vocabulary subtest of the Wechsler Adult Intelligence Scale and absence of dementia as determined by a score of 24 or higher on the Mini- Mental State Examination ("MMSE").

[0195] Potential subjects were excluded based on the following exclusion criteria:

• Unlikely or unable to comply with investigational medication dosing

requirements;

• Diagnosis of major depressive disorder, Alzheimer's or vascular dementia as defined according to the Mini International Neuropsychiatric Interview

("MINI")/Diagnostic and Statistical Manual of Mental Disorders (4th edition) Text Revision ("TR") criteria;

• Past or current history of: o a neurological or psychiatric disorder that could have affected cognitive function; o inflammatory gastrointestinal disease such as Crohn's Disease or ulcerative colitis; o cancer other than basal cell carcinoma; o clinically significant cardiac abnormality as measured by 12-lead ECG;

• Any other medical condition or intercurrent illness not adequately controlled, which, in the opinion of the study investigator, may have put the subject at risk when participating in the study or may have influenced the results of the study or affected the subject's ability to take part in the study;

• Clinically significant abnormal screening results (e.g., haematology,

biochemistry) on screening or vital signs that fell outside the normal range for this population, which in the opinion of the study investigator affected the subject's suitability for the study;

• Changes to prescribed medication for a medical condition within 4 weeks of the baseline visit; • Omega-3 supplementation within 4 weeks of the baseline visit or during the study treatment period;

• Currently taking anticoagulants or daily dose of aspirin greater than 325 mg.

• Cough or flu remedies containing opiates or antihistamines within 2 weeks of the baseline visit or during the 6-week treatment period; and

• Known allergy to any ingredients of the study drug or placebo.

[0196] Ninety-four subjects were randomized into one of six groups: 1 g E-EPA daily (n=23), 2 g E-EPA daily (n=24), 4 g E-EPA daily (n=24), 1 g placebo daily (n=7), 2 g placebo daily (n=8), and 4 g placebo daily (n=8). E-EPA was provided as 500 mg soft gel capsules containing >96% E-EPA and 0.2% dl-a-tocopherol as an antioxidant. Placebo capsules contained 467 mg of liquid paraffin and 0.2% dl-a- tocopherol. Ninety-one subjects completed the study. Two subjects in the 2 g E-EPA group and one subject in the 2 g placebo group discontinued the study.

[0197] The study consisted of a screening visit, a training visit, and four study visits. At the screening visit, subjects' eligibility was determined through cognitive tests (verbal paired associated learning [PAL] subscale, vocabulary subtest, Memory Assessment Clinics Questionnaire [MAC-Q], mini mental state evaluation [MMSE] and MINI [mini international neuropsychiatric interview; sections 1 and 2 of

Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) plus dysthymia]), haematology, clinical chemistry and 12-lead electrocardiogram (ECG). At the training visit, subjects were shown how to use the CDR computerized system. Subjects took study drug for 6 weeks and on Days 0, 14, 28 and 42, subjects underwent the CDR cognitive test battery.

[0198] At screening cognitive testing and suitability for the study were assessed using the Verbal Paired Associates 1 (Wechsler Memory Scale), Vocabulary Subtest of the WAIS, MAC-Q, MMSE and MINI (DSM-IV Sections 1 and 2 plus Dysthymia).

[0199] A selection of tasks from the CDR computerized cognitive assessment system were administered at Visit 2 (training visit), Visit 3 (baseline), Visit 4 (Day 14), Visit 5 (Day 28) and Visit 6 (Day 42). Parallel forms of the tests were presented at each testing session. All tasks were computer-controlled, the information presented on high resolution monitors, and the responses recorded via a response model containing two buttons: one marked 'no' and the other 'yes'. Five CDR composite scores were used as the primary/secondary outcome variables. The task titles were:

• Word Presentation

• Immediate Word Recall

• Picture Presentation

• Simple Reaction Time

• Digit Vigilance

• Choice Reaction Time

• Spatial Working Memory

• Numeric Working Memory

• Delayed Word Recall

• Word Recognition

• Picture Recognition

• Bond-Lader Visual Analogue Scales of Mood and Alertness

• Screen, Using the Computer Mouse

[0200] To ensure consistency of approach, full training on the cognitive tests and CDR test battery was provided to study site staff and study subjects. The results of each variable were automatically recorded using the machine interface developed by CDR.

[0201] Blood samples (10 mL) were collected at Visit 1 (screening) and at Visits 4, 5 and 6. Analysis was performed by MSR Lipid Analysis, Scottish Crop Research Institute, Dundee, UK. The screening sample acted as baseline for the EFA measurements. Lipid was extracted from plasma, serum and RBC suspensions and converted into fatty acid methyl esters which were analyzed by gas chromatography to give fatty acid profiles as micrograms fatty acid per gram of sample ^gFA/g) and normalized area percent.

[0202] All randomized subjects with at least 1 visit post-baseline were included in the Intent to Treat ("ITT") population, regardless of treatment actually received.

[0203] All randomized subjects that completed the study, excluding significant protocol deviators, were defined as the Safety Per Protocol population. An Efficacy Per Protocol population was based on the Efficacy completers. The intercept of the Safety and Efficacy Per Protocol populations defined the Study Per Protocol

Population.

[0204] All randomized subjects that received at least 1 dose of study medication were included in the Safety Population.

[0205] Summary statistics were provided for the ITT and Study Per Protocol Populations separately for all composite scores, major and supportive variables.

Summary statistics were performed for both the unadjusted and difference from baseline data (i.e. the difference from the time matched predose assessments on Day 0). Summary statistics were calculated by treatment, day and time-point. The summary statistics comprised n, mean, median, SD, standard error of mean ("SEM"), minimum and maximum values.

[0206] Difference from baseline data for each major variable was evaluated by an Analysis of Covariance ("ANCOVA") using SAS® PROC MIXED Version 8.2. Fixed effects for treatment, day, time point, treatment by day, treatment by time point, treatment by day by time-point were fitted. Subject within treatment was fitted as a repeated effect using the repeated statement. The compound symmetry covariance structure was used. Subjects' time-matched predose assessments on Day 0 were used as a covariate in the analysis.

[0207] Least squares means (LS means) were calculated for treatment by day, treatment by time-point and treatment by day by time-point interaction. This formal analysis was conducted for the ITT and Study PP Populations separately. [0208] Safety evaluations were based on the safety population. Safety and tolerability were assessed in terms of AEs, vital signs, 12-lead ECG, clinical laboratory data, medical history, and study drug compliance. Safety and tolerability data were presented by treatment group.

[0209] RBC and plasma EFA data were collected at baseline, Day 14, 28 and 42 and summarized by visit for each treatment group. Change from baseline and percent change from baseline were also summarized. ANCOVA comparison of ethyl-EPA dose groups and ethyl-EPA versus placebo was performed.

[0210] Efficacy Results.

[0211] All CDR cognitive test battery analyses were completed for the ITT and Study PP analysis populations.

[0212] For the Intent-to-Treat Analysis for Power of Attention, there was no statistically significant effect of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions. There was no LS mean difference between active treatment and placebo at any time-point.

[0213] For the contributing subtasks Simple Reaction Time and Digit Vigilance Speed, there were no statistically significant effects of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions. For the subtask measure Choice Reaction Time, there was a statistically significant treatment by day interaction (p=0.011).

[0214] For the Study Per-Protocol Power of Attention, there was no statistically significant effect of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions. There was no difference between active treatment and placebo at any time-point.

[0215] For the subtasks Simple Reaction Time and Digit Vigilance Speed, there were no statistically significant effects of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions. For the subtask measure, Choice Reaction Time, there was a statistically significant treatment by day interaction (p=0.013).

[0216] The Intent-to-Treat Continuity of Attention and the contributing subtask Digit Vigilance Targets Detected tests showed no statistically significant effect of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions.

[0217] For the Study Per Protocol Continuity of Attention test, there was no statistically significant effect of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions.

[0218] For the subtask Digit Vigilance Targets Detected, there was a statistically significant treatment by time-point interaction (p=0.040).

[0219] For the Intent-to-Treat Quality of Working Memory test, there was a statistically significant treatment by day interaction (p=0.019).

[0220] For the contributing subtask Spatial Working Memory Sensitivity Index, there was a statistically significant treatment by day interaction (p=0.015).

[0221] For Numeric Working Memory Sensitivity Index, there was a statistical trend for a treatment by day interaction (p=0.089).

[0222] For the Study Per-Protocol Quality of Working Memory test, there was a statistically significant treatment by day interaction (p=0.021).

[0223] For the contributing subtask Spatial Working Memory Sensitivity Index, there was a statistically significant treatment by day interaction (p=0.014).

[0224] For the Intent-to-Treat Quality of Episodic Secondary Memory test, there was no statistically significant effect of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions. The LS mean differences showed overall statistically significant decreases versus placebo for ethyl-EPA 1 g and 2 g (p=0.040 and p=0.035, respectively). [0225] For the contributing subtasks Immediate and Delayed Word Recall Accuracies and for Word and Picture Recognition Sensitivity Indices, there were no statistically significant effects of treatment or treatment by day, treatment by time- point or treatment by day by time-point interactions. For Immediate Word Recall Accuracy, the LS mean differences showed statistically significant decreases for 1 g on Day 14 (p=0.028) and for 2 g on Day 28 (p=0.017). There were statistically significant decreases versus placebo for 1 g and 2 g at AM 1 (p=0.040 and p=0.028, respectively). There were statistically significant decreases for ethyl-EPA 1 g versus placebo on Day 14 at PM 2 (p=0.020) and for 2 g on Day 28 at AM 1 (p=0.006). For Word Recognition Sensitivity Index, the LS mean differences showed statistically significant decreases for ethyl-EPA 1 g on Day 28 (p=0.024) and for 4 g on Day 42 (p=0.038) versus placebo. There was a statistically significant decrease for 4 g at PM 2 (p=0.045) and a statistically significant decrease for 4 g versus placebo on Day 28 at PM 2 (p=0.030). For Picture Recognition Sensitivity Index, the LS mean differences showed statistically significant decrease for 1 g versus placebo on Day 28 at AM 2 (p=0.017) and at PM 2 (p=0.040). For the Study Per-Protocol Quality of Episodic Secondary Memory test, there were no statistically significant effects of treatment, nor treatment by day, treatment by time-point or treatment by day by time- point interactions. The LS mean differences showed overall statistically significant decreases versus placebo for 1 g and 2 g (p=0.043 and p=0.036, respectively).

[0226] For the contributing subtasks Immediate and Delayed Word Recall Accuracies and for Word and Picture Recognition Sensitivity Indices, there were no statistically significant effects of treatment or treatment by day, treatment by time- point or treatment by day by time-point interactions. For Immediate Word Recall Accuracy, the LS mean differences to placebo showed statistically significant decreases for ethyl-EPA 1 g on Day 14 (p=0.024) and for 2 g on Day 28 (p=0.017). There were statistically significant decreases for 1 g and 2 g at AM 1 (p=0.038 and p=0.029, respectively) and for 1 g at AM 2 (p=0.048). There were statistically significant decreases for 1 g versus placebo on Day 14 at PM 2 (p=0.019) and for 2 g on Day 28 at AM 1 (p=0.006). [0227] For Word Recognition Sensitivity Index, the LS mean differences to placebo showed statistically significant decreases for 4 g on Day 42 (p=0.038) and for 1 g on Day 28 (p=0.027).

[0228] For Picture Recognition Sensitivity Index, the LS mean differences showed statistically significant decreases versus placebo for 1 g on Day 28 at AM 2 (p=0.020) and PM 2 (p=0.026).

[0229] For Intent-to-Treat Speed of Memory and the contributing subtasks Spatial and Numeric Working Memory Speeds and Word, and Picture Recognition Speeds, there were no statistically significant effects of treatment, nor treatment by day, treatment by time-point or treatment by day by time-point interactions. For Spatial Working Memory Speed, the LS mean differences showed a statistically significant benefit versus placebo for ethyl-EPA 4 g on Day 14 at PM 1 (p=0.048) and a trend for a benefit for 4 g on Day 42 at AM 1 (p=0.061). For Picture Recognition Speed, there were trends for benefits versus placebo for 1 g on Day 14 at AM 2 (p=0.084) and on Day 28 at AM 1 (p=0.085).

[0230] For Study Per-Protocol Speed of Memory and the contributing subtasks Spatial and Numeric Working Memory Speed and Word, and Picture Recognition Speed, there were no statistical significant effects of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions.

[0231] For Intent-to-Treat Self-Rated Alertness, there was no statistically significant effect of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions. The LS mean differences showed a statistically significant decrease in ratings for ethyl-EPA 2 g on Day 28 (p=0.047) versus placebo. There was a statistically significant decrease in ratings versus placebo for 2 g on Day 28 at AM 2 (p=0.041). For Study Per-Protocol Self-Rated Alertness, there was no statistically significant effect of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions. The LS mean differences showed a statistically significant decrease in ratings for ethyl-EPA 2 g on Day 28 (p=0.035) versus placebo. There was a statistically significant decrease in ratings versus placebo for 2 g on Day 28 at AM 2 (p=0.033). [0232] For Intent-to-Treat Self-Rated Contentment, there was a statistically significant treatment by day interaction (p<0.001). The LS mean difference to placebo showed no statistically significant effects. For Study Per-Protocol Self-Rated

Contentment, there was a statistically significant treatment by day interaction

(p<0.001). The LS mean difference to placebo showed no statistically significant effects.

[0233] For Intent-to-Treat Self-Rated Calmness, there was no statistically significant effect of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions. For Study Per-Protocol Self-Rated Calmness, there was no statistically significant effect of treatment, nor any treatment by day, treatment by time-point or treatment by day by time-point interactions. The LS mean differences showed a statistical trend for an increase in ratings versus placebo for ethyl-EPA 4 g on Day 42 at PM 1 (p=0.071).

[0234] A post-hoc analysis compared the individual placebo groups (1 g, 2 g and 4 g paraffin oil) with the corresponding ethyl-EPA doses.

[0235] The pattern of data provided evidence that ethyl-EPA 4 g might improve speed in the attention based measures. For Power of Attention, there was an overall benefit versus the corresponding placebo for 4 g on Day 42. The subtask Simple Reaction Time showed improvements in performance for 4 g at PM 2 collapsed across days and at several time-points on Days 14 and 42. The improvements for 4 g were most pronounced in the Choice Reaction Time task, where there was an overall benefit versus corresponding placebo for 4 g, reflecting a benefit for 4 g over placebo on all study days. The pattern of improvement in performance throughout the assessment days was quite convincing as the improvements began on Day 14 with improvements seen at 2 time points, whereas on Day 42 ethyl-EPA 4 g was superior to placebo at every time point.

[0236] For Continuity of Attention, there were isolated declines or improvements in performance, but there was no general pattern of effects and it was considered unlikely these differences were due to the study compound. For Quality of Working Memory and in the subtask measure Numeric Working Memory Sensitivity Index, there were, as in the original analyses, only isolated improvements and declines in performance that were most likely not treatment-related. However, for Spatial Working Memory Sensitivity Index, there was an overall benefit for ethyl-EPA 4 g over placebo on Day 42 in the Study PP Population, which corresponds to the improvements seen for the attention based measures.

[0237] For Quality of Episodic Secondary Memory and contributing subtasks, there were a number of decreases for ethyl-EPA that could be explained by the pre-existing differences in performance between the placebo and active treatment groups which was seen in the original analyses. In contrast to the original analysis, the subtask measures of Speed of Memory showed some signs of improvement in performance for active treatment, mostly for 1 g versus placebo. For Self-rated Alertness and Self-rated Contentment, the 1 g dose showed decreases in ratings on Days 14 and 28. However, these decreases were not correlated with a decline in performance in the CDR attention tasks. As with the original planned analysis, there were no differences between active treatment and placebo in Self-Rated Calmness.

[0238] Safety Results.

[0239] Subjects who used less than 80% of the prescribed dose were to be considered non-compliant; other than those subjects who withdrew for other reasons only 1 subject fell into this category and was withdrawn.

[0240] Overall, 139 treatment emergent AEs ("TEAEs") were reported by 62 (66.0%) of subjects during the study. Most TEAEs were considered mild in severity and unrelated to study drug. More TEAEs were reported for the ethyl-EPA treatment groups (105 events) compared to the placebo treatment groups (34 events). One SAE was reported for the ethyl EPA 2 g treatment group and 3 subjects discontinued due to TEAEs: 2 subjects from the ethyl-EPA 2 g treatment group (the primary reason for discontinuation for 1 of these subjects was non-compliance), and 1 subject from the placebo 2 g treatment group.

[0241] There were no deaths during the study. No TEAEs were Definitely Related to the study drug. One subject receiving 1 g ethyl-EPA experienced nausea that was Probably Related to the study drug. Another subject receiving 4 g ethyl-EPA experienced diarrhea that was Probably Related to the study drug; another subject receiving 2 g placebo also experienced diarrhea that was Probably Related to the study drug. Five subjects experienced nausea that was Possibly Related to the study drug; two were in the 1 g ethyl-EPA cohort; one was in the 2 g ethyl-EPA cohort; two were in the 4 g ethyl-EPA cohort. One subject receiving 2 g placebo experienced headache that was Possibly Related to the study drug. All other TEAEs were Not Related or Unlikely Related to the study drug, and included nasopharyngitis (n=3), cystitis (n=2), cough (n=7), toothache (n=2), pharyngolaryngeal pain (n=2), back pain (n=2), pollakiuria (n=2), influenza-like illness (n=2), headache (n=15), diarrhea (n=2), and nausea (n=l).

[0242] One subject with a history of transient ischaemic attack, hypertension and osteoarthritis of the hand and osteopaenia receiving 2 g ethyl-EPA experienced worsening epigastric chest pain 17 days after the start of the study and 9 days after the last dose of the study drug. A planned endoscopy revealed oesophagitis and a small hiatus hernia. The subject was treated with omeprazole, which settled her symptoms. The subject had taken felodipine, rosuvastatin, aspirin, glucosamine, and quinine within 14 days of the onset of her symptoms. The study investigator determined that her symptoms were unrelated to the study drug and withdrew the subject from the study. No other Serious Adverse Events occurred during the study.

[0243] Essential fatty acid parameters in plasma and RBCs was measured at baseline and on Day 14, 28 and 48 (shown in Tables 6 - 11). Notable changes for these parameters occurred in the ethyl-EPA treatment groups at Days 14, 28 and 42 compared to placebo. EPA, DPAn-3 and EPA/AA ratio values increased substantially from baseline, in plasma and RBC, to Day 42 for the ethyl-EPA 1 , 2 and 4 g treatment groups, but remained similar to baseline in the placebo treatment groups. AA, DHA and DGLA values decreased substantially from baseline, in plasma and RBC, to day 42 for the ethyl EPA 1, 2 and 4 g treatment groups, but remained similar to baseline in the placebo treatment groups. The difference in EPA, AA (RBC only), DPAn-3, DGLA (1 g only for plasma) and EPA/AA ratio levels in the plasma and RBC were significantly (LS means, p<0.05) different for the ethyl-EPA 4 g treatment group compared to the ethyl-EPA 1 g and 2 g treatment groups. Table 6. EFA Parameter EPA (Plasma and RBC) Mean change from Baseline to Days 14, 28 and 42.

EFA Etfevl-i-PA Plsc«lra

Parameter L ^ 1

S 4 ^ =¾5) N" = 2 » (N = 24) = i) <N = 5> i =8)

2.3 24 24 S S ess: (SD) 483(31.03) 44.i 2S.iili 4i?.l (17.23) 47.5(2:6.41) 2.1 m.m 42.5 (ll.&S)

Dav 14; a 23 22 24 7 7 S

Mass (BE?) .2 (26.61) i24.Si ;42.25> 207.7 iS70S) 1.6 ;24.6&;. 1.2-'i9.«2; 2L9 (32.91)

Dav 22. n 22 24 7 7

Me mm &) mm) 142.2 (46.23 215.2: (5S.6S) 6.5 (15.46) li (13.54) 1.3 (14.03;

Dsv42:n 2i 22 24 7 7

MM (SB) c2.y ;7 43:. 133.4 (43..34) 224.6 (£0.©) 1 (2* ) ( LIS) 4.4(23.32)

1 or 2 ? van S4g

LS esa -iii-S -£0.§ - - -

Ci -123.& -ISO -72.7.. -49.0 - - - - p-vslits -m - - - - SC

Brsvriine: ts 25 24 24 7 7

Mess (SD) is.§(g.si) i . 20.4(5. " ; 19.3(6.55) 17.2(4.54)

Day 14: a 21 22 24 7 7 §

Mess (SD) 123 39) 2630.15) 39.5ft3.lS) •0.5 i'6.32 0.Q (7.17) 2.6 (6.73)

Dav 2%: a 22 22 24 7 7 :j:

Mess(SD 14.5(10.47) 32.5(10.11) 50-.2 (1:".S2) 1.5 (4.16) 0.0 i'7.i½ 0,6 (4.42}

Dav 42: a 23 22 24 7 8

Mea&CSB) 17.6 m.sg 38.3 (12.46) 52.5 (20.56) -8.2 (5S0) 1.&(8.δί> •0.2 (6.97)

I or 2 s ws? *4g

LS eaa -24.4 -ll.g -

CI -27.6. -21.2 -15.3.-8.6 - - -

«0.001 0 1 - - - -

Table 7. EFA Parameter AA (Plasma and RBC) Mean change from Baseline to Days 14, 28 and 42.

EFA Ethyl EPA Ffacebe

Paraiaefer lg

lg(N = 23) - s 3 I H

0? = 24) ( = 7) ( = S ( = S)

Piasias

Bsss&se: a 2.? 24 24 7 g 8

Mesa (SB) 202.5 (44.45) 227.3 (42.26} 20.9 C42.SO) 10.7 i?\.<& 24S.0

(35.63) «20.24: (53.52)

Dav 14: a .23 72 24 7 7 S

Mesa (SB) -P.? (22.20) (22.13) -27.2 (28.SS) O.S (40.50) -14.4 -5.9 (25.00)

51.9.45)

Day 2S: a 22 22 24 7 S esss (SO) -11302.13} 21.6(22.32) -43.7 (32.24) 3..-2S -7.4 (23.72) -16.4

(31.42)

Day 42: a 23 γ> 2:4 7 7 S

Mesa (SB) -3.7 ;3L.3 ; -27 Q&.I6) -4S.3 C 220 8.2 (20.3-10 -11..5 -IS.8

-O.SS: (2512) s4g

LS eea 4.2 153 - - - -

CI -8.0.16 3,4, 27.S - - - p-vskie 0.013 - - - -

RBC

Bss.elins; a 23 14 .24 7 s g

Meas (SD) 171.2 {IS.75) 172 {22.7§) 1"·.0 :2?.17 76.4 152.S 1S0:4

(17.65) (!7.3¾ (23.SS)

Day 14: a .23 24 7 ? 8

Meki'SB) -3.1 QLfiS) -3.1 (23.S4 -1.5.7 (2Ss.?<V> -3.3 i'22.75) IS) (IS.20) -S.l (27.53)

Dav 2S a .22 2.2 14 7 1 S

M sn;SD; -17.0 ; 20.69; -14,1 (26.SS) -22.8 (2S.5© 5.2 (22.95) -S.2 (26.S5)

Day 42: a 23 22 24 7 - S

Messs (SD) -14.2 ;.27.i9) -iS.S (25.52) .34.4(3144) 9 J (16..58) -13.6

(33.49) i«2gvtm _4g

IS Mesa 8.4 9.S

I 2.0.14.9 33.16.2 - - - p-vslue 0.010 0.003 - - - -

Table 8. EFA Parameter DHA (Plasma and RBC) Mean change from Baseline to Days 14, 28 and 42.

Figure imgf000068_0001

Mess 5'SD) 711 (3Φ.43) 75.1 (24.02) 7s.s m 73.7(14.21) 73.3 (27.74) 76.7 (13.6S)

Day 14: a .23 22 .24 7 S

Mesas (SO) -≤,4{i3.3-0j -5,4(14..29> -ΙΟ.ί f 13.35) . m -0.!? i.23.i 13.SQi.S5)

DOT 28: n 22 22 24 7 7 §

MsssK'SD) -6.5(1573) -S..1 (1 -13.5(14.10) 4.7(16.31) -0.6:2.2):;.

Ba. 2:n 23 22 24 f 8

MeWi'SD -5.4(18.17) -6.0 (.16 W -13.8 (15.31) !LS (21. ) 0.S {17.57, 6.2 (13.40)

LSMesa -0.S 1.5 - - - -

CI -7.3, 17 -IS. S.l .- - p--vslus 0..S10 0/44 - -

EEC

BsssSne: B. 23 2 24 8 8

MessifSD) 66.5 (iS.65) 64.S (17.65) 6S.3 (14.24) 71.1 i74S) 66.2 (15. S3;

Dav 14: a 23 22 .24 7 8 esE (SQ) -liHS ii) -63 (9.m -.i..5(ii. -ΰ..2 (1.2.37?) -3.4 <i.2.5S)

Dav 28: a 22 22 24 7 7 S

Mes&CSD) -6.4(Π. 7 -6.2 (S.34> -£.7(11.0) n.c (I2. -0.3 a ·.>?·.. 1.1 (12.14)

Dav 42: a 23 2.2 24 8 esa (SB) -".002.20) -<5.3 (942) -13.8 (13.76) -4.1 (12.02) 4. ii2 >4) •0. (1.7.63)

Ϊ or 2 g ves-ssss 4 s

LS&fesa 1.0 10 - - -

CI -3.5, 4 -3.5. 5 .- - - p-vslus 0.674 0.664 - - - -

Table 9. EFA Parameter DPAn-3 (Plasma and RBC) Mean change from Baseline to Days 14, 28 and 42.

Figure imgf000069_0001

21.1 (6,62) 29.7 (4.50> 21.7(4.6») I?.? . 1st· (4 9) 19. (2.67)

Dav 14-: a 2) 22 24 1 7 S

2.2 (4. S)

Figure imgf000069_0002

1 or 2 = "«:::;:.42:

LS Nlsaa -P 5 - - - -

CI -Ϊ7.6, -12.7 ■41 A -.?.! - -.

p-vskia 0.0SI - - -

RBC

Bss.eiiae: n 23 24 .24 7 S

Mesa(SD) 34.1 (143) 33.2: (4.5 _> 34.5 (4.34) 24.0 (4.27) 33.0 (1.20) 32.4 (2.41)

Day 14-: a 23 22 24 7 7 S

3 (3.S3) 5.6 (6.2S: 5.4 ' 5.)?; -2 S (4 §≤.: .0.) a. iS) -a.5(4..74)

Da:V 2S a 22 22 24 7 7 S

Mess (SB) 3.3 (5.42) 9.4 6.74) 12. 5.ί¾ 0.1 (4.51) -(·.£ (4.03)

Day 42: a 23 ·>·· 24 7 S

MeasfSD) 6.5 (6..!¾ 13.2 (7.23) 16.2 (.$.¾?} -1.5(4.64) 2.2 i.444 i -S.f (6.03)

LS asn -62 -2.5 - - - -

CI -' S. -4.7 -4.1, -i.S - - - p-vslae --■'■flJuOl 0.Q02 - -

Table 10. EFA Parameter DGLA (Plasma and RBC) Mean change from Baseline to Days 14, 28 and 42.

EFA Fsrame r Efiyl-EPA 1

Is 4 ^

2g( =24) 4 g ( = 24)

<N = 7l

Bsiiim : is. 23 24 24 s 7

Mesa (SB) 51.2(15.01} 53.5 {14.12} 57.1 (14.73) 51.5(9.20) 41.6 (10.30) 52.6(7.74)

Dav 14: a 23 7 24 7 7 S

-ί0.4{!δ.ί?0) -14.! (6.SE) ■ 22.9 :.:>.0-0; -4.1 <¾.(Π: -0.0 -l.iMll.5S)

Day 28: a 2? 24 7 S

Mess(SD) ■ 16.2 -24.2 (10.73) -4.·ί 57.43) -5.6 (5.91) 1.5 Hi '

Dav 42: s 2? 24 7 S

Mean (SB) •.'.4 iS. !) •1 3 l> -22.5 ( 0. S7} -13 (12.50) 0.9(934} 0.5(11.04)

1 or 2 g vs :

LS Mesa 3.7 2.5 - - - ci 0,4.7.0 ■ 09 ' S - - - -

3.028 0143 - - -

RBC

BssaSne: a 2. .24 24 8 7

Mesa (SB) 23.0 (5.1® 2i.iM5 ""1 2:2.4 .06; 19.7 (5. S7) 22,4(4.91)

Dav 14: a 23 22: 24 7 7 S

Mess S[» -2.7 (3.52) ■2.5:3.541 ■ 3.3 :4.;0; -1.5 ;23)8: 0.2 (.1.7$) -1.8(4.00)

Bav 2:S: a 22 22 24 7 S eeaCSD) -3.Sp.31} -4.5ii.5S) -7.1 (4.S3) 0.2 (3.63) -0.7 (4.05) ■0.7 {3.81)

Day 4251 23 24 - S

Mesa. (SB) -3.5 :.4..5i; -5.3 (3.65) -S.0i4.9-:} -1.5(4.53) 19 (3. SI} -1.1(531) or : g ·«¾·

LSMesn 1.5 1.5 - - - ci 0.2.2.9 0.1, 23 - - -

0.02? 0.032 - - - -

Table 11. EFA Parameter EPA/AA (Plasma and RBC) Mean change from Baseline to Days 14, 28 and 42.

EtiiTl-EPA Pianho

EFA Parameter

2 g is

(Ν = 23ϊ ( = 24 i = 7) CN = S> (T = Ss

23 24 24 7 § s

Mesa (SB) 0.2(0.14) 0.2(0.12) δ. ΐ0.07ί 0.2 ίδ.ίί) 0.2 ( .0··}

Dr,' 14: a 5 22 24 7 7 s

Mess (SB) 0.3 (0.4) 0.6(0.23) LI f¾.2S) .δ (O.Si?) 0.0:0.12: O.i (0.12)

Dav 2S:a 22 22 24 7 7 S

Mean <SD) S f 0.20) SKS.3 13 (3.42·· 9.0 (0:.:0S) 0.0 C0.O9) 0.0:0.0:0

Dav 42: n 23 22 24 7

G.J £0.24) Ο.7Ϊ0.2Ο) 3.3 $.45} 0.01022: S.000 )

LS Svfesa -Q.6 -S.41 - - - -

CI -0.731. -0.475.

-0597 -0.341

js-vs¾ue 0.0i 0.0 1

RBC

Bsssiiiss: u 23 24 24 7 § s

Mesa (SB) O.i (0.07> o.i ®m 0.1 :.Q.&4; O.i <8. ) 0.1 ii.OcO o.i $)

Ds i4ra 23 22 24 7 7 $

Me¾iiSB) 0.1 (0.04) 0.2 (0.04) 0.3 {0.87s 0.0(0.03) -0.0 (5.05) 0.0(0.(53)

Dav 2S: a 22 22 24 7 7 g

Mean (SCO ■3.1 (0.05) 3.52(0.06) 0.4(0.11) 0.0(0.01} -5.0 (0.04; 0.0(0,02)

Dav 42: n 23 72 24 7 7

M«m(SD) 0.1 (0.06) 0.3 (0.0(5) 03 :.0. ; 0. ί"δ.03) - .0;0.r,5; 0.0(0.03)

Sor.lg«mat4£

LS esa -SIS 45.11 - - - -

CI -0.204. - -0.126, - - - - 0.162 0.SS5

J>-VSilK '■am - - - -

Claims

What is claimed is:
1. A method of reducing a C-reactive protein level in a subject having metabolic syndrome and fasting triglycerides of at least 500 mg/dL, the method comprising:
identifying the subject as having metabolic syndrome; identifying the subject as having fasting triglycerides of at least 500 mg/dL; and
orally administering to the subject about 4 g per day of ethyl eicosapentaenoate for a period of time effective to reduce a C-reactive protein ("CRP") level in the subject.
2. The method of claim 1, wherein the reduction in CRP level is at least about 20%, about 27%, about 28%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, about 78%, at least about 80%, at least about 90%, or greater than about 90%.
3. The method of claim 1 or claim 2, wherein the reduction in CRP is compared to a second subject having metabolic syndrome and fasting triglycerides of at least 500 mg/dL who has not received the ethyl eicosapentaenoate.
4. The method of any preceding claim, wherein the ethyl eicosapentaenoate
comprises at least about 90%, at least about 95%, or at least about 96% of the fatty acids present.
5. The method of any preceding claim, wherein the subject is not administered DHA or an ester thereof.
6. The method of any preceding claim, wherein the period of time is at least about 12 weeks
7. The method of any preceding claim, wherein the step of orally administering the ethyl eicosapentaenoate further reduces one or more of:
a triglyceride level associated with the subject;
a non-HDL-C level associated with the subject; and an apolipoprotein B level associated with the subject.
8. The method of any preceding claim, wherein the subject has a fasting baseline triglyceride level of 500 mg/dL to 1500 mg/dL.
9. The method of any one of claims 3 to 8, wherein the subject and the second subject each have fasting baseline triglyceride levels of 500 mg/dL to 1500 mg/dL.
10. The method of any preceding claim, wherein the subject is on statin therapy.
11. A method of reducing a C-reactive protein level in a subject on statin therapy who has metabolic syndrome and fasting triglycerides of about 150 mg/dL to 499 mg/dL, the method comprising:
identifying the subject as having metabolic syndrome and as having fasting triglycerides of about 150 mg/dL to 499 mg/dL; and
thereafter orally administering to the subject about 4 g per day of ethyl eicosapentaenoate for a period of time effective to reduce a C-reactive protein ("CRP") level in the subject.
12. The method of claim 11, wherein the reduction in CRP level is at least about 20%, about 27%, about 28%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, about 78%, at least about 80%, at least about 90%, or greater than about 90%.
13. The method of claim 11 or claim 12, wherein the reduction in CRP is compared to a second subject on statin therapy who has metabolic syndrome and fasting triglycerides of at least about 150 mg/dL to 499 mg/dL who has not received the ethyl eicosapentaenoate.
14. The method of any one of claims 1 1 to 13, wherein the ethyl eicosapentaenoate comprises at least about 90%, at least about 95%, or at least about 96% of the fatty acids present.
15. The method of any one of claims 1 1 to 14, wherein the subject is not administered DHA or an ester thereof.
16. The method of any one of claims 1 1 to 15, wherein the period of time is at least about 12 weeks
17. The method of any one of claims 1 1 to 16, wherein the step of orally administering the ethyl eicosapentaenoate further reduces one or more of:
a triglyceride level associated with the subject;
a non-HDL-C level associated with the subject; and
an apolipoprotein B level associated with the subject.
18. The method of any one of claims 1 1 to 17, wherein the statin is one or more of atorvastatin, rosuvastatin and simvastatin.
19. A method treating a subject with mixed dyslipidemia and metabolic syndrome on statin therapy, the method comprising:
identifying the subject as having mixed dyslipidemia and metabolic syndrome; and
thereafter administering to the subject about 4 dosage units per day, each dosage unit comprising about 900 mg to about 1.1 g of ethyl eicosapentaenoate for a period of at least about 12 weeks to effect a reduction in triglycerides.
20. The method of claim 19 wherein the subject has baseline triglycerides of 200 mg/dl to less than 500 mg/dl.
21. The method of claim 19 or claim 20, wherein the subject has coronary heart disease or a coronary heart disease risk equivalent.
22. The method of any one of claims 19 to 21, wherein administration for the period of at least about 12 weeks effects a reduction in one or more of: CRP, non- HDL-C, Apo B, LDL-C, total cholesterol, and VLDL-C.
23. The method of any one of claims 19 to 22, wherein the dosage units comprise capsules.
PCT/US2014/063494 2013-10-31 2014-10-31 Methods of treating hypertriglyceridemia WO2015066512A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US201361898133 true 2013-10-31 2013-10-31
US61/898,133 2013-10-31
US201361900078 true 2013-11-05 2013-11-05
US61/900,078 2013-11-05

Publications (1)

Publication Number Publication Date
WO2015066512A1 true true WO2015066512A1 (en) 2015-05-07

Family

ID=53005213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/063494 WO2015066512A1 (en) 2013-10-31 2014-10-31 Methods of treating hypertriglyceridemia

Country Status (1)

Country Link
WO (1) WO2015066512A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9585856B2 (en) 2009-04-29 2017-03-07 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
US9855240B2 (en) 2013-02-19 2018-01-02 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9855237B2 (en) 2009-04-29 2018-01-02 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278879A1 (en) * 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
US20110218243A1 (en) * 2010-03-04 2011-09-08 Amarin Pharma, Inc. Compositions and methods for treating and/or preventing cardiovascular disease
WO2013074930A1 (en) * 2011-11-18 2013-05-23 Howard University Methods for treating leishmaniasis
US20130189355A1 (en) * 2012-01-06 2013-07-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
WO2013148136A1 (en) * 2012-03-30 2013-10-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278879A1 (en) * 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
US20110218243A1 (en) * 2010-03-04 2011-09-08 Amarin Pharma, Inc. Compositions and methods for treating and/or preventing cardiovascular disease
WO2013074930A1 (en) * 2011-11-18 2013-05-23 Howard University Methods for treating leishmaniasis
US20130189355A1 (en) * 2012-01-06 2013-07-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
WO2013148136A1 (en) * 2012-03-30 2013-10-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855237B2 (en) 2009-04-29 2018-01-02 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US9585856B2 (en) 2009-04-29 2017-03-07 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
US9918955B2 (en) 2012-06-29 2018-03-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9610272B2 (en) 2012-06-29 2017-04-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9623001B2 (en) 2012-06-29 2017-04-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9693985B2 (en) 2012-06-29 2017-07-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9693986B2 (en) 2012-06-29 2017-07-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9693984B2 (en) 2012-06-29 2017-07-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9918954B2 (en) 2012-06-29 2018-03-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9855240B2 (en) 2013-02-19 2018-01-02 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Similar Documents

Publication Publication Date Title
US4681896A (en) Pharmaceutical and dietary composition
Maki et al. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women
Lavie et al. Omega-3 polyunsaturated fatty acids and cardiovascular diseases
Calder et al. Understanding omega-3 polyunsaturated fatty acids
Sellmayer et al. Effects of dietary fish oil on ventricular premature complexes
Nodari et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy
McKenney et al. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia
Gertsik et al. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder
Fetterman et al. Therapeutic potential of n-3 polyunsaturated fatty acids in disease
O'keefe et al. From Inuit to implementation: omega-3 fatty acids come of age
Stahl et al. The role of omega-3 fatty acids in mood disorders
Saravanan et al. Cardiovascular effects of marine omega-3 fatty acids
Reiffel et al. Antiarrhythmic effects of omega-3 fatty acids
US20050027004A1 (en) Methods of treating senile dementia and Alzheimer&#39;s diseases using docosahexaenoic acid and arachidonic acid compositions
Mori et al. Effects of varying dietary fat, fish, and fish oils on blood lipids in a randomized controlled trial in men at risk of heart disease.
Lemke et al. Dietary intake of stearidonic acid–enriched soybean oil increases the omega-3 index: randomized, double-blind clinical study of efficacy and safety–
US20070021504A1 (en) Composition and/or method for preventing onset and/or recurrence of cardiovascular events
US20050171200A1 (en) Use of EPA and DHA in secondary prevention
US20110178105A1 (en) Clinical benefits of eicosapentaenoic acid in humans
Yokoyama et al. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS)
EP2022495A1 (en) Composition for preventing the occurrence of cardiovascular event in multiple risk patient
US20110071176A1 (en) Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2308493A1 (en) Ameliorating or therapeutic agent for dyslipidemia
US6667064B2 (en) Composition and method for treatment of hypertriglyceridemia
EP0296751A1 (en) Essential fatty acid compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14858671

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14858671

Country of ref document: EP

Kind code of ref document: A1